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ABSTRACT 
 
Urinary tract infections (UTI) are one of the most common human bacterial infections, caused 
by uropathogenic E. coli (UPEC). Conventionally, UTI’s are treated with antibiotics, such as 
sulpha-mathoxazole/trimethoprim and ampicillin. However, a significant proportion of UPEC 
strains have become resistant to these antibiotics, resulting in a significant burden on the 
health care system worldwide. Bacteriophages (phages) that target E. coli strains could 
provide an alternative treatment for UTIs, particularly those resistant to antibiotics. This study 
aimed to screen a variety of environmental samples for phages that target a UPEC strains and 
characterize these phenotypically and genotypically, towards the development of a candidate 
phage preparation for treatment for antibiotic-resistant UPEC. 
 
Environmental samples (including faeces cattle, sheep, horse, goat faeces, river water, raw 
cow milk and mud) were collected from various sources around the City of Cape Town and 
screened for phages using an E. coli laboratory strain; K-12 MG1655. Lytic phages against E. 
coli MG1655 were purified and host-range testing was conducted against a panel of 11 UPEC 
strains form the E. coli reference collection (ECOR). These lytic phages were characterized 
phenotypically using transmission electron microscopy (TEM) using negative staining and 
genotypically using restriction enzyme HaeIII. 
 
In total, 41 phages that were lytic against MG1655 were isolated from six different 
environmental samples. Of these, 31/41 (76%) were lytic against 7/11 (64%) UPEC 
strains tested. Four phages (16-3, 16-4, 16-5 and 16-7; all isolated from raw milk) had the 
broadest host range of all the phages screened, being lytic against 4/11 (36%) UPEC strains. 
UPEC strain ECOR-40 was the most susceptible of the E. coli strains tested, being 
susceptible to 18/31 (58%) of the lytic phages isolated. In contrast, four UPEC strains 
(including ECOR-14, -60, -62 and -64) were not susceptible to any of the phages isolated. 
Ninety percent (28/31) of the isolated phages were structurally similar to four known phage 
families; including Myoviridae, Siphoviridae, Inoviridae and Rudiviridae. The remaining 
10% (3/31) had structures that did not resemble any of the known phage families. DNA was 
x  
isolated from all 31 phage isolates to screen for similarities in restriction patterns of 
isolates. Of these, RFLP banding was clear for 5/31 samples; which showed that 5/5 
phages were unique based on their banding patterns. In conclusion, this study 
demonstrated the existence of several unique E. coli phages in nature and their ability to 
target several of the UPEC strains known to cause UTI. Although time did not allow for 
sequencing of the full genomes of those isolates with unique characteristics in this study, 
this should be a priority for this research going forward. 
 
KEYWORDS: Urinary tract infections, uropathogenic E. coli, bacteriophages, antibiotic 
resistance 
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1 INTRODUCTION 
 
 
The emergence of antibiotic resistance in South Africa and worldwide has made it challenging 
to treat bacterial infections. Over-prescription of antibiotics to treat human diseases, their 
casual use in treating plant/animal diseases, in agriculture to accelerate crop and animal 
growth, and the decline in development of new antibiotics over the past decades have 
contributed significantly to the increase in antibiotic resistance 1. Combining multiple 
antibiotics together in treatment has been one approach implemented to control 
development of antibiotic resistance in bacterial pathogens. However, the dissemination of 
multi-drug resistant bacteria such as Mycobacterium tuberculosis, Enterococcus species, and 
Pseudomonas aeruginosa2 indicates that this multi-antibiotic strategy may not be as effective 
as needed or too little too late. New and advanced approaches to microbial chemotherapy 
need to be explored urgently to avoid the occurrence of a catastrophic post-antibiotic hazard. 
As an attempt to address this, bacteriophages are being explored as biocontrol agents in food 
additives and in both veterinary and clinical settings, where they have been used to treat 
human bacterial infections in Eastern Europe for over 100 years.  
 
1.1 Polymicrobial nature of urinary tract infections (UTIs) 
 
One of the most common infections in humans are urinary tract infections (UTIs)3–6,         
affecting the urethra, bladder, ureter and kidney7. Although commonly caused by 
uropathogenic E. coli (UPEC), several other bacterial species have been associated 
with UTI, including Escherichia coli, Staphylococcus. aureus, Klebsiella pneumonia, Proteus 
mirabilis and P. aeruginosa8. Of these, UPEC strains account for by far the majority (>75%) 
of UTIs6. In addition, Enterococcus and Candida spp. have also been associated with UTIs, 
although less commonly9,10. Although UTIs are more common in the lower urinary tract 
(urethra and the bladder), some UTIs ascend and reach organs in the upper urinary tract 
(ureters and kidneys) which results in more severe symptoms such splenomegaly (spleen 
enlargement as a complication of an abscessed kidney infection) and pyelonephritis (kidney 
inflammation)7. Uncomplicated UTIs are generally acute and community acquired, with less 
diverse etiology comprising almost exclusively of infections with UPEC.6 Complicated UTIs, 
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on the other hand, are sometimes poly-microbial (involving a diversity of microbes 
including E. coli, S. aureus, K. pneumonia, P. mirabilis and P. aeruginosa8), and more likely to be 
influenced by underlying risk factors, such as catheterization, diabetes, old age or having a 
spinal cord injury4. Although the etiology of complicated UTIs is more diverse, 
uncomplicated UTIs are much more common4. In general, women are more prone to UTIs 
than men, with >70% of UTI cases being reported in women and these are further 
complicated by the high recurrence rate of UTI in most women.6,11. 
 
E. coli is a rod-shaped gram-negative bacterium, that is widely distributed in nature, 
inhabiting water and soil environmental niches, as well as the gastrointestinal tract 
(GIT) of most mammals12–14. E. coli has been associated with a number of clinical diseases in 
humans, mainly involving the intestines and urinary tract. E. coli K-12 MG16555 is a non-
pathogenic laboratory strain of E. coli, originally derived from a commensal of the human gut, 
called K-12, and hence designated K-12 MG1655. The MG1655 E. coli strain is the first E. 
coli strain with a large genome (>4 megabases) to be sequenced in 1997 by F. Blattner 
and has been used as a model organism for wild-type E. coli over the years because it is 
uncomplicated to culture14,15. 
 
There has been ten E. coli pathotypes described to date, based on the clinical syndromes they 
exert and their place of action in the human body; including (1) uropathogenic E. coli (UPEC), 
(2) diffusely adhering E. coli (DAEC), (3) enterotoxigenic E. coli (ETEC), (4) enteropathogenic 
E. coli (EPEC), (5) enterohemorrhagic E. coli (EHEC), (6) enteroaggregative E. coli (EAEC), 
(7) shiga-toxin-producing enteroaggregative E. coli (STEAEC), (8) enteroinvasive E. coli (EIEC), 
(9) adherent invasive E. coli (AIEC), and (10) meningitis-associated E. coli (MAEC)15,16. 
Except for AIEC, which has been associated with Crohn’s disease, these cause diarrhea 
(DAEC, ETEC, EPEC, EHEC, EAEC, STEAEC, and EIEC). Furthermore, both UPEC and MAEC are 
extra-intestinal pathogens causing infections such as UTIs, septicemia, osteomyelitis 
and neonatal meningitis15–17 . 
 
 
1.2 The virulence of UPEC strains 
 
Women with shortened and/or wider urethras are at a higher risk of suffering from retrograde 
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ascent of microbes, in which microbes of fecal origin populate the bladder and sometimes the 
kidney18. Child birth and sexual intercourse also contribute to this, as they allow for the fecal 
microbes to be massaged up the urethra into the bladder18,19. Vaginal colonization with UPEC 
 
 
strains generally precede bladder epithelial colonization, and this is worsened in women who 
experience recurrent UTIs, whereby vaginal UPEC colonization is extended even during 
asymptomatic infections20,21. Recurrence of UTIs make them more challenging to treat, and 
more than 25% of women with UTIs experience recurrent infections within 3 to 6 months22. 
Of these recurrent UTI cases, ~60% are caused by the same bacterial strain that caused the 
initial infection4,7. Gilbert et al.7 showed that vaginal microbiota play an important role in UTI 
recurrence using mice as a model, and that transient exposure to Gardnerella Vaginalis, a 
facultative anaerobe commonly associated with bacterial vaginosis (BV), triggers the 
movement of E. coli from latent reservoirs in the lower reproductive tract to the bladder 
lining7. Consistent with this, Gardnerella and Lactobacillus species have been isolated from 
urine, both of which are commonly found as part of the vaginal microbiota supporting the 
hypothesis that the urinary tract is exposed to vaginal bacteria, and vice versa 23–25. 
Interestingly, there is a 3-fold increase in E. coli adherence to buccal, vaginal and voided 
bladder epithelial cells in women with recurrent UTIs4, a phenomenon previously thought to 
be connected with diminishing antibacterial adherence host defense mechanisms26. 
 
Several specialized adhesive structures on the outer surface of uropathogens have been 
identified to play a central role in colonization, including the outer protein Lam B, the outer 
membrane protein C (OmpC), terminal glucose moieties with a βl,3 glycosidic linkage and 
filamentous cell surface structures (flagella27 and pili28)29–32. In the case of UPEC, these 
filamentous structures are called type 1 fimbrae and P pili, and have generally been found on 
the surface of most E. coli strains4. Unlike the E. coli P pili, type 1 fimbrae are thought to play 
a larger role since they are one of only two factors thought to contribute significantly to 
urovirulence, the second factor being the production of -hemolysin8,33. Each E. coli fimbrae 
has an adhesion molecule at the tip, called FimH, which allows E. coli to interact with host cell 
receptors on the bladder epithelium, thereby enabling bacterial attachment4. Fimbriation by 
E. coli isolates has been associated with urovirulence4,34, with pathogenic E. coli strains found 
to have higher expression of type 1 fimbrae compared to commensal E. coli strains35–38. High 
expression levels of fimbrae by E. coli is thought to enhance their recognition by receptors on 
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bladder epithelial and immune cells, which increase the likelihood of E. coli surviving antibiotic 
treatment39. In addition to mediating host cell entry or adhesion, E. coli type 1 fimbrae also 
allow UPEC strains to translocate out of the host cell or be internalized into the late 
endosomal compartment, where they establish a quiescent intracellular reservoir that 
contributes to UTI recurrence and other serious complications of recurrent UTIs (such as 
kidney damage and splenomegaly) 7. In such a quiescent state, UPEC strains are better able 
to evade immune surveillance and resist antibiotic treatment which primarily targets actively 
replicating pathogens 40. UPEC strains also avoid immune detection by suppressing host 
immunity 41,42. UPEC strain CFT073 was able to block activation of host NF-κB, thereby 
decreasing secretion of inflammatory cytokines which was associated with an increase in type 
1 pilus-mediated uroepithelial apoptosis43. The ability of UPEC strains to evade and/or 
suppress host immunity indicates the extent at which these organisms have evolved and will 
have to be studied and understood further in order to effectively treat or eradicate them. 
 
Unlike the type-1 pili, an E. coli surface virulence factor, -hemolysin is a pore forming 
intracellular virulence factor with a wide spectrum activity against leukocytes, erythrocytes, 
endothelial and renal epithelial cells44,45. At low concentrations -hemolysin, it induces 
apoptosis of its target cells and stimulates bladder epithelial cell exfoliation46,47. Whereas, at 
high concentrations, it results in host cell lysis, which in turn facilitate UPEC dissemination 
across mucosal barriers to gain access to host nutrients, iron supplies and impair immune 
effector cell function8,14,44,45,48,49. 
 
Although type 1 fimbrae and hemolysin are the dominant mechanisms facilitating UPEC 
pathogenesis, there are other less common factors that can be of importance in facilitating 
urovirulence, such as afimbrial adhesins (filamentous structures without fimbriation; which 
have the same mode of action as the fimbriated structures i.e. type 1 fimbrae), iron- 
acquisition systems required to steal the host’s iron stores; and other secreted toxins such as 
cytotoxic necrotizing factor 1 (which cripples the host’s immune effector cells hence 
facilitating bacterial dissemination) 33. 
 
Four phylogenetically distinct groups of E. coli have been described, using multilocus enzyme 
electrophoreses (MLEE) to compare allelic variation of 12 enzyme encoding loci 50. These 
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include E. coli groups A, B1, B2 and D. Pathogenic E. coli strains primarily belong to group B2 
and group D to a lesser degree, whereas commensal strains predominantly belong to either 
group A or group B1 51–53. Strikingly, some pathogenic strains of UPEC, specifically those in the 
ECOR collection belong to phylogenetic groups known to harbor commensal strains, such as 
group D54,55. A study characterizing UPEC isolates from South Korean patients showed that 
almost 80% (46/58) belonged to group B2, only 16% (9/58) belonged to group D, and less 
that 5% (1/58) belonged to group A and B1 (1/58)56. This indicates that it is not 
uncommon for some pathogenic strains of E. coli to be categorized under a phylogenetic 
group considered to contain commensal strains. This further suggests that there might be 
an overlap of alleles used to group the strains into phylogenetic groups amongst 
commensal and pathogenic strains or that the criteria used to group these strains may 
not be stringent. 
 
1.3 Burden of antibiotic resistance in treating UTIs 
 
International recommendations for the treatment of UTI involves one of the following first 
line antibiotics; trimethropim-sulphamethoxazole (TMP-SXT), amoxicillin combined with 
clavulanic acid, ampicillin, nitrofurantoin or fluoriquinolones for five days57,58. However, the 
frequency of treatment failure for conventional antibiotics to E. coli has increased over the 
last decade 19,59–64. Amongst the 58 UPEC isolates tested from the South Korean cohort 
described previously, 13 of the 14 E. coli virulence factors (fimH, sfa, papA, hylA, cnfl, aer, 
afac, feoB, Irp2, iroN, iha, eae, stb and It-1 ) that were screened for antibiotic resistance 
against Aminoglycosides (gentamicin, tobramycin and amikacin), Penicillin (ampicillin), 
Carbapenems (imipenem and meropenem), Cephalosporins (cefotaxime, ceftazidime, 
cefepime and cefoxitin), Monobactam (aztreonam), Chloramphenicol, Sulfonamide 
(trimethoprim), Fluoriquinolones (ciprofloxacin) and Tetracycline were noted.  E. coli 
groups B2 and D exhibited the highest number of the virulence genes and were the most 
resistant to the antibiotics tested for compared to the other phylogenetic groups.56 
However, since none of the UPEC isolates appeared to be resistant to cefoxitin, cefepime, 
ceftazidime, and chloramphenicol, the Korean study confirmed that these could still be 
used in therapy in that region56. 
6  
Some of the strategies employed by E. coli to resist antibiotics include: (i) expression of 
antibiotic resistance genes65–68; (ii) biofilm formation (which renders them resistant to the 
immune system and antibiotics)3; and (iii) establishing a protected intracellular niche within 
bladder epithelial or immune cells7. In the face of antibiotic pressure, UPEC strains undergo 
horizontal gene transfer, involving the acquisition of mobile genetic material/cassettes (which 
could include plasmids, transposons or bacteriophages) that often result in antibiotic 
resistance57,69. Horizontal gene transfer is one of the mechanisms often used by bacteria to 
adapt to the new environment, by which they are able to transfer resistance from one 
bacterium to the next for survival 70–72. Over time, the antibiotic sensitive UPEC strains will be 
targeted and destroyed while the strains that have acquired antibiotic resistance will survive 
through natural selection, and pass it on to their offspring1,57,69. A study investigating the 
antibiotic susceptibility profile of 227 UPEC isolates from Jordan University of Science and 
Technology found that 82% of the isolates that were resistant to at least three antibiotic 
classes (including amoxicillin, nalidixic acid,  and cefoxitin) produced extended- spectrum 
beta-lactamase (ESBL) which is an enzyme encoded by antibiotic resistance genes SHV,TEM 
and CTX_M73 and can confer antibiotic resistance to -lactam antibiotics through the 
hydrolysis of the -lactam ring (a four atom ring structure found in -lactam antibiotics) 
which then deactivates the antibacterial properties of -lactam antibiotics 74. In addition, 
recombination within E. coli with foreign genetic material and spontaneous mutations are 
other mechanisms that enable emergence of drug resistance mutations75 .A study 
conducted by Manikandan et al.8 screened several different bacterial strains that have been 
associated with UTIs, including E. coli, but also S. aureus, Klebsiela pneumonia, P. mirabilis 
and P. aeruginosa, for susceptibility to various antibiotics (including amoxicillin, cephalexin, 
gentamycin, nalidixic acid, ciproloxacin, cotrimaxozole and TMP-SXT). They found that most 
strains were highly resistant to nalidixic acid and TMP-SXT (the drug of choice in treating 
UTIs), although E. coli were more resistant to most conventional UTI antibiotics than the 
other strains, followed by L. pneumonia and P. aeruginosa. The higher prevalence of antibiotic 
drug resistance in E. coli compared to the other UTI causing bacterial species was attributed 
to the presence of the type 1 dihydrofolate reductase (Dhfr) gene, which has been shown to 
confer resistance to TMP-SXT in particular and is widespread across gram-negative 
bacteria as a result of selective pressure resulting from the extensive use of TMP-SXT 8,77,78. 
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Trimethoprim is a folate analog which binds to the catalytic site of the Dhfr enzyme, 
however over- transcription of this enzyme can result in mutations which can reduce the 
affinity of folate analogs for this Dhfr enzyme and thus result in a bacterial phenotype that’s 
resistant to drugs containing trimothoprim78. 
 
Alternatively, biofilm formation by E. coli is another potential mechanism for the decreased 
susceptibility of UPEC isolates to commonly prescribed antibiotics3. A study by Chibeu et al.3 
characterized 250 UPEC isolates for their biofilm forming competences and anti-microbial 
resistance, and reported that almost a fifth produced biofilms and more than 75% were 
resistant to at least one of the antibiotics tested. Another study examining the association 
between biofilm formation and antibiotic susceptibility in 100 UPEC isolates from 166 urine 
specimens of UTI patients demonstrated that of the 72 strains producing biofilm, 100% were 
resistant to chloramphenicol and amoxiclav (amoxicillin combined with clavulanic acid), 86% 
were resistant to gentamicin and cefotaxime, 84% were resistant to cotrimaxozole and 
piperacillin/tazbactam, 75% were resistant to tetracycline and 70% were resistant to 
amikacin73. 
 
Hiding within host cells is another mechanism used by E. coli pathogens to survive antibiotics 
and evade immune surveillance40. Internalization of E. coli into host cells is mediated by type 
1 fimbrae which also enhance their intracellular survival within phagocytes such as 
macrophages and neutrophils35,79,80 . However, the exact mechanism through which this 
process takes place is not known, as internalization of pathogens by phagocytes commonly 
leads to degradation through destructive enzymatic action and toxic host chemicals42. The 
ability of E. coli to escape from intracellular acidified phagosomes within phagocytes, either 
(1) by lysing the phagosome to escape into the cytosol where they will gain access to 
nutrients; or (2) by altering their physiology and characteristics of the phagosome 
compartment, has been proposed as a mechanism whereby immune evasion occurs42,81,82. 
While not all intracellular pathogens can escape these membrane-bound compartments 
within phagocytes (like Chlamydia and Salmonella typhimurium), E. coli shares this property 
with Mycobacterium tuberculosis that are able to propagate intracellularly by inhibiting 
phagosome acidification and maturation into a phagolysosome42. Inhibiting phagosomal 
acidification through the use of drugs like concanamycin and bafilomycin (which are potent 
inhibitors of a proton motive force V-ATPase shown to mediate this process), resulted in the 
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death of intracellular E. coli strains42,83. This implies that this may be one of the key 
intracellular strategies employed by E. coli to remain viable. The continued increase in cases 
of antibiotic resistant UPEC strains should serve as a warning of the potential dangers of 
antibiotic resistance among these common pathogens. In order to prevent the emergence 
and spread of antibiotic resistant UTI strains, empiric treatment directed at UTIs will have to 
change. 
 
1.4 Bacteriophages as alternative treatment to antibiotics 
 
As antibiotic resistance (particularly multi-drug resistance) increases, there has been renewed 
interest internationally in alternative microbicidal treatments, including the use of 
bacteriophages to kill specific bacterial pathogens. First tested in the early 1900’s by Felix 
d’Hérelle and collaborators1 at the Pasteur Institute in France, phage therapy uses specific 
viruses that target bacteria to kill disease-causing bacterial pathogens. Although this method 
of phage therapy was overtaken by the antibiotic revolution in the America’s and most other 
parts of the occidental world, it has successfully been used for the treatment of bacterial 
infections in a number of eastern European countries such as Russia, Armenia, Ukraine, 
Georgia and Poland84. Phage treatment was most often used as last resort to treat chronic 
bacterial infections that did not respond to antibiotic treatment85. And although used in 
previously mentioned European countries, the republic of Georgia is the only place that has 
officially incorporated phage therapy in their standard of care for both prophylactic and 
treatment purposes86. For instance, Intestiphage and Pyophage are the two primary phage 
cocktails primarily used in Georgia 86. Both these phage cocktails target different bacterial 
species, Pyophage targets pus-causing infections caused by E. coli, P. aeruginosa, S. aureus, 
Streptococcus and 2 Proteus species86.In contrast, Intestiphage cocktail targets enteric 
bacteria, particularly gut-acquired strains of P. aeruginosa and S. aureus86. 
 
One of the major concerns of burn wounds in the past was the development of bacterial 
infections which usually impeded skin grafting85. To overcome this concern, phage cocktails 
were applied topically to the wound with high success rates. Thirty patients with burn wounds 
from Egypt that were experiencing sepsis caused by antibiotic-resistant P. aeruginosa, 
bandages immersed in 1010 pfu/ml of phages were applied three times daily, of which 60% of 
patients (18/30) reported good skin grafting, 40% (12/30) experienced outstanding skin 
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grafting, and 26.7% (8/30) were negative for bacterial infections87. More evidence on the 
successful use of phages to treat burn wounds came from Georgia during the Soviet era. For 
examples, three laborers with methicillin-resistant S. aureus (MRSA)-infected burn wounds 
were treated with phage preparations made up of a polymer saturated with ciprofloxacin and 
lytic phages, following antibiotic failure, and all subsequently were shown to have cleared 
MRSA within a week of treatment. Since MRSA had already been shown to be resistant to 
ciprofloxacin, treatment success was attributed to the presence of phages in the mixture88. In 
Poland, E. coli and S. aureus were the two main bacterial species that were targeted with 
phages as they were the main cause for most bacterial infections with antibiotic resistance85, 
and a panel of phages against these two bacterial species are typically kept in a central 
repository to be accessed for treatment. 
 
1.5 General characteristics of phages 
 
Phages have been classified into 14 subfamilies, including 204 genera and 873 species 89–91, 
with four distinct morphotypes having been described (Figure 1.1): tailed, polyhedral, 
filamentous, or pleomorphic (meaning they can modify their structure in response to 
environmental conditions)92. Some morphotypes are more prevalent than others, with tailed 
phages being the most ubiquitous in any geographical niche92,93. Phages can either be double 
or single stranded DNA or RNA viruses, that either have linear or circular genomes,92,94 often 
influenced by the phage morphotype94. DNA phages have more commonly been described in 
the literature than RNA phages. Phage genome size tends to correlate with the size of the 
capsid, and tailed phages tend to have larger genomes than non-tailed phages92. 
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Figure 1.1: A schematic representation of the four phage morphotypes. (A) Tailed structure 
seen for phages such as T4 and Lambda belonging to the families Myoviridae and Siphoviridae, 
respectively. (B) Polyhedral structure seen in phages such as φX174 belonging to the family 
Microviridae. (C) Filamentous structure seen in phages such as fd and MVL1 belonging to the 
 
family Inoviridae. (D) Pleomorphic structure seen in phages such as L2 and PSV belonging to 
the families Plasmaviridae and Globuloviridae, respectively. Figure adapted from Ackerman 
et al 92 
 
Tailed phages either have contractile or non-contractile tails (Figure 1.1A). Phages of this 
morphotype are the most prevalent described in nature, including three phage families: 
Myoviridae, Siphoviridae and Podoviridae and the order Caudovirales92. Tailed phages have 
regularly been identified across a wide range of host organisms, making up ~96% of bacterial 
viruses from 14 subfamilies, with Siphoviridae making up about 61% of those identified, 
Myoviridae about 25%, and Podoviridae about 14%92.Myoviridae, Siphoviridae and 
Podoviridae all have hexagonal heads, with Myoviridae family generally having bigger heads 
than the other types to accommodate their larger genome size94. Although the tail length of 
Myoviridae and Siphoviridae are similar, the rigid contractile tails of Myoviridae phages 
discriminates them from flexible and usually spiral non-contractile tails found in Siphoviridae 
phages 92. Phages in the Podoviridae family have a non-contractile tail which is shorter than 
their heads94. 
 
Polyhedral phages are distinguished by their polygonal nature, which is often the shape of 
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most phage capsid (Figure 1.1B). This morphotype is demonstrated in phages belonging to 
the families Corticoviridae, Tectiviridae, Leviviridae, Microviridae and Cystoviridae92. The 
most studied phage with this morphotype are those belonging to the family Microviridae and 
are often in association with tailed phages in nature92,93. 
 
Filamentous phages (Figure 1.1C) are long and flexible in structure but lack the typical 
polygonal capsid of tailed phages. The phage families Inoviridae, Rudiviridae and 
Lipothrixiviriadae exemplify this morphotype92, with Inoviridae being the most common and 
best characterized. Some of the best characterized Inoviridae phages include M13, f1 and fd 
and have been isolated from E. coli 95. Phages of this morphotype strictly infect gram negative 
bacteria, and their length is determined by the genome size they encapsulate92,94. 
Filamentous phages are released from their bacterial host by secretion, requiring a proton 
 
pump and ATP, rather than by causing bacterial lysis 95–97. As a result, filamentous phages 
frequently cause chronic infection of their bacterial hosts. 
 
Pleomorphic phages (Figure 1.1D) tend to acquire unique shapes which has been attributed 
to their ability to survive under more diverse environmental conditions 92,93. Phages families 
with this type of morphotype include Plasmaviridae, Globuloviridae, Bicaudiviridae and 
Apullaviridae – all of which are not well characterized due to their how scarce they are in 
nature 92,93. Phages of this morphotype are known to have a very limited host range92,93. 
 
1.6 The two distinct phage lifecycles 
 
Given the vast abundance and diversity of phages in various ecosystems that exist in nature, 
it is important to understand how they interact with other organisms in each niche, as this 
interaction is likely to play an important role in shaping other biological systems 98. The 
interaction of phages with other organisms is best understood through their lifecycles. 
Traditionally, phages have two distinct types of lifecycles: the lytic and lysogenic lifecycle 
(Figure 1.2). 
 
The lytic lifecycle involves the phage infecting its host and, within the cytoplasm, using the 
host’s resources to assemble its particles and consequently resulting in host lysis (without 
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integrating is genetic material into the DNA of the host) 48,70,99. Phages that undergo the lytic 
lifecycle are termed virulent phages. 
 
The lysogenic lifecycle occurs when the phage does not lyse the host following infection, 
instead it integrates its genome into the circular DNA chromosome of the host and continues 
to replicate with host’s genomic material 48,70,99. These phages are alternatively known as 
temperate phages Although less common, temperate phages can also exist as an 
extrachromosomal plasmid within the cytoplasm of the host (Figure 1.2F).12,98  During their 
lysogenic cycle, they are called prophages 103,104. Once a bacterial host acquires a prophage, 
the host is then designated a lysogen69. In some instances, bacteria that harbor more than 
one prophage are said to be poly-lysogenic 69,103,105. An interesting example of a poly- 
lysogenic bacteria is an enterohemorrhagic E. coli strain O157 which was found to harbor 
eight prophages (sp1 to sp8) and six prophage-like elements (SpLE1 to SpLE6) which are 
basically sequences indicative of genetic mobility, also called the mobilome 103,106. Some of 
these prophages have been linked to virulence of the bacterial host because they encode 
genes for some of the bacterial hosts most vigorous virulence factors, such as shiga toxins 1 
and 2 103. Furthermore, the poly-lysogenic nature of some bacteria has been associated with 
phenotypic changes 69,103,105. For instance, a prophage can interfere with an expression of a 
specific gene by inserting itself in the middle of the bacterial gene locus. The host gene can 
later be reestablished as a consequence of prophage excision, which leads to the 
manifestation of multiple phenotypic traits in the bacterial hosts 69,103,105. 
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Figure 1.2: Schematic diagram of lytic and lysogenic lifecycles of phages. Initially a phage 
adsorbs (A) and inserts its genetic material into the host cell (B), through a series of factors, 
the genetic material will either be incorporated into the bacterial chromosome where it is 
now a prophage (E), or the phage will use the host replication machinery to produce new viral 
components and assemble (C), then lyse the host in a lytic infection (D). If the prophage 
is established, it will replicate and divide with the host (F) and if its triggered through 
prophage induction it will then enter the lytic lifecycle and result in host lysis (G). 69,70                              
 
1.7 Factors that induce expression of prophages 
 
Although lysogeny is a common amongst bacterial populations 101,103,104,107, environmental 
stressors can trigger the release of the prophage from the genome of the bacterial host. This 
process is known as prophage induction 100,101,103. Among the many factors that result in 
induction of prophages from their bacterial hosts, treatment with Mitomycin C (an antitumor 
agent known to bind to the CpG island for DNA crosslinking108) or exposure to UV C radiation 
are among the best described100–102. Prophage induction results in the activation of the SOS 
response in lysogens109. The SOS response in bacterial hosts is a high-fidelity DNA repair 
mechanism that is induced in response to DNA damage and involves the use of two bacterial 
proteins: LexA and RecA. LexA acts by repressing DNA transcription hence known as negative 
regulator, whereas RecA activates transcription and is termed a positive regulator of this 
repair system 109. For instance, exposing lambda () phage lysogens to UV radiation or 
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Mitomycin C was shown to result in RecA-dependent cleavage of the  prophage repressor 
cl, which represses the phage lytic genes. Studies using RecA and/or cl deficient bacteria 
have shown that cl is not cleaved and the lytic cycle is no longer inhibited 110. Following 
prophage induction, viral replication occurs through the lytic lifecycle (Figure 1.2D). 
 
1.8 Alternate phage life cycles: pseudo-lysogenic or the carrier state 
 
Although lytic and lysogenic phage lifecycles have been well-described in literature 67,98,104, 
there is evidence to suggest that there might be other less studied and understood lifecycles 
67,98,104. An example of a less understood phage lifecycle is pseudolysogeny and the carrier 
state 98,100,101. Pseudo-lysogeny does not involve phage genome integration or bacterial host 
cell lysis and has caused some debate about whether this is an actual phage lifecycle or a 
suspended state of phages after infection. It has been suggested that this might be a 
protective state, by serving as (1) an intracellular retreat for phages in an environment with 
low host cell concentrations, or (2) a state in which phages avoid poor replication or 
degradation of their DNA in a nutrient starved host cell that is not conducive to neither the 
lytic or lysogenic lifecycle 98,111,112. An example of a pseudo-lysogenic phage is P22 that was 
isolated from Salmonella typhimurium. P22 was only expressed when its genetic material was 
not integrated into the host genome and it was found to be asymmetrically separated 
following cell division 113. This state has also been observed in phages against P. aeruginosa. 
103 Although considered to be a recent discovery, it was originally witnessed by Frederick 
Twort 114 in the early 1900s. 
 
 
With the carrier state, the phage neither enters the lysogenic nor the lytic lifecycle. Instead, 
the phage particles persist within the host cell and their progeny is released through budding 
or asymmetrically passed on to daughter cells following cell division 116. Unlike 
pseudolysogeny, the carrier state is thought to be established and maintained in a nutrient- 
rich environment, and results in either a chronic or a productive infection 116,117. For instance, 
it is suggested that virions of the filamentous phage M13 known for strictly infecting gram 
negative bacteria92,94, undergoes this state since they are not be released by host cell lysis but 
by leaking through holes created by extruding virions that form mesosomes on the bacterial 
cell wall (which are folded invaginations on the surface of bacterial membrane meant to 
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increase the surface area of the membrane) 118,94. It has also been suggested that some E. coli 
filamentous phages undergo the carrier state, resulting in high concentrations of phages while 
concomitantly slowing down the growth rate of the host replication. 95 
 
Pseudolysogeny, lysogeny and the carrier state may all represent states of coexistence 
between the phage and their hosts. In some cases, it has been suggested that these two states 
allow for the preservation of the phage nucleic acid material for an extended period of time 
and could partly explain the large environmental reservoirs of phages in nature112. 
 
1.9 Phages against E. coli and other UTI causing pathogens 
 
There is very little published data on the use of phages as treatment for UTIs. Most of the 
literature that has focused on demonstrating the existence of lytic phages against 
uropathogens is derived from in vitro studies 119–124. E. coli-specific phages, termed 
coliphages, have commonly been described in the literature, which may reflect the vast 
abundance and diversity of E. coli in nature14,90,99,120,125–132. Several well-characterized 
coliphages that have been described to date, including tailed (belonging to the families 
Myoviridae, Siphoviridae and Podoviridae), filamentous (belonging to the Inoviridae 
family), and polyhedral phages (belonging to the Microviridae family)92. Microscopic 
analysis of 
coliphages isolated in nature revealed that they are mostly tailed and predominantly belong 
to the Siphoviridae family 92,93. Demerec et al.133 first isolated coliphages from an E. coli strain 
at the Cold Springs Harbor laboratories, isolated from sewage or fecal matter around the 
mid-1940s, that are available to the public today through the ATCC 134. The Cold Springs 
Harbor repository was later accessed by Delbrück et al.135 who propagated seven coliphages 
using E. coli strain B, which he later designated type 1 (T1), T2, T3, T4, T5, T6 and T7. Of these, 
T3 and T7 are thought to be related to each other whereas T1 and T5 are different to the rest 
of the T phages and to each other. 136 T2, T4 and T6 are the commonly described coliphages 
and have been shown to be genetically related and are now termed T-even enterobacterial 
phages. 137,138 Morphological analysis of the T-even phages revealed a contractile tail and 
elongated head, suggesting that they belong to the Myoviridae family. The T-even phages 
continue to be explored for their utility in treating E. coli infections 120,137. 
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Lambda (λ) is another well described coliphage, discovered in 1950 by an American 
microbiologist Esther Lederberg, 139 while she was streaking mixtures of E. coli strains. The 
mixture of a UV-light treated mutant strain of E. coli K-12 crossed with its wildtype parental 
strain yielded plaques on agar plates. She later realized that the plaques were caused by 
bacterial viruses, which were later named phage Lambda (λ) 139. Lambda phage is one of 
the notable phages that can undergo both the lytic and lysogenic lifecycle139,140. It 
belongs to the family Siphoviridae, being tailed with a capsid encapsulating its dsDNA 
genome 140. Phage Lambda continues to be used as a model organism in microbial and genetic 
settings. 
 
KEP10 is one of the seven coliphages isolated from environmental water in Kochi, Japan 120. 
Its morphology and genotype resemble that of T4 (classified as a Myoviridae phage) and 
was shown to have a broad host range (able to lyse 67% of 42 UPEC strains tested). The 
ability of KEP10 and T4 phages to treat UTIs were tested in vivo using BALB/c mice who 
had been given UTI through injecting bacterial cells of UPEC ECU5 suspended in saline 
transurethrally. In this UTI model, mice were injected with 1.3X10 KEP10 or 1X10 T4 viral 
particles peritoneally, which resulted in a significant decrease in mortality compared to the 
control mice 120. KEP10 continues to be explored further due to its broad host range. 
  
Three more tailed phages ɸAPCEc01, ɸAPCEc02, and ɸAPCEc03, isolated from three adult 
patients, were also found to infect UPEC strains 125. Morphological analyses revealed that the 
first two phages belonged to the family Myoviridae and resembled the T4 and rV5 phages. 
The last phage resembled the T5 phage, belonging to the family Siphoviridae. These three 
phages were tested for their ability to clear 16 E. coli strains in culture. Each one of the three 
cleared at least two of the 16 E. coli strains to the multiplicity of infection (MOI) between 
10-3 and 105. One strain in particular, called E. coli DPC6051, was susceptible to all phages 
individually and in the cocktail 125. Combining the phages with ciprofloxacin, individually or as 
a cocktail, led to the inhibition of E. coli growth and establishment of resistant strains125. 
 
It is clear that E. coli is predominantly sensitive to tailed phages, this susceptibility suggests 
that tailed phages may have adapted to infecting E. coli over time, possibly increasing the 
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sensitivity of E. coli strains to these phages and hence increasing the robustness of these 
coliphages to E. coli strains. The abundance and diversity of coliphages further increases their 
chances of discovery which perhaps explains why most studies focus on isolating them from 
environmental sources such as raw sewage, rivers, dams and fecal matter 120,125,134. 
 
1.10 Advantages and disadvantages of phages versus antibiotics 
 
Although the use of phages as therapy was eclipsed by antibiotics in the twentieth century in 
most developed countries (including the United States of America, the United Kingdom and 
Western and Central Europe), this approach has some advantages over antibiotics 141. Certain 
antibiotics, like tetracycline, are bacteriostatic rather than bactericidal, and therefore do not 
kill the bacteria but limit their growth by interfering with DNA replication, protein production 
and overall metabolism 142, which can facilitate development of antibiotic-resistance 143,144. 
In contrast, lytic phages tend to be bactericidal, resulting in the bacterial cell death 142. Owing 
to their narrow host range, phages tend to minimally disrupt commensal bacterial 
communities 4,70,145. In most instances, phages are capable of infecting only a few strains even 
within one bacterial species. Phages are rarely able to infect two closely related bacterial 
geneses145. Resistance strategies developed by bacteria against antibiotics cannot be adopted 
by phages since they kill bacteria differently from antibiotics 1,4,70,71,84,141. As a result, phages 
can be applied to treat antibiotic-resistant bacteria 1,4,70,71,84,141. 
 
Despite some of the advantages that phages offer over antibiotics, they do pose a certain 
level of risk. Phages being administered as replication-competent entities could potentially 
aid in evolution of commensal bacterial strains into pathogenic ones 121. By lysing their hosts, 
phages can result in the release of bacterial components (including toxins like 
lipopolysaccharides [LPS]) that may induce immunity in the human or animal host 146 and 
lead to septicemia. While cases of septicemia have been observed, this occurs much less 
frequently than observed with the use of antibiotics147. Some clinical trials using phages have 
shown that immune responses are elicited by phages 148. Most studies have shown that the 
innate immune system is primarily responsible for systemic clearance of phages 68,149,150. For 
example, in experiments using mice injected intravenously with phages showed that Kupffer 
cells (which are specialized phagocytes in the liver) and spleen macrophages phagocytosed 
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T4 phages rapidly after the mice were exposed to phages, leading to rapid clearance of the 
therapeutic agents 149. It was argued that some of these side effects can be mitigated by 
carefully removing endotoxins from phage preparations, which can be removed using organic 
solvents 151. 
 
Only obligate lytic phages are used for phage therapy, since they have to be able to target 
and kill bacteria. The use of lysogenic phages in therapy carries a higher risk of introducing 
foreign genetic material such as antibiotic resistance genes, and pathogenicity islands into the 
bacterial host genome by transduction. Transduction, which can either be generalized or 
specialized, involves transfer of genetic material among bacterial strains or genera using the 
phages as the transducing vehicle 70,71,152. Generalized transduction is often the result of a 
lytic phage infection whereby the phage encapsulates host nucleic acids, burst the bacterial 
host cell, and moves to infect surrounding susceptible bacteria. Specialized transduction, on 
the other hand, involves the incorporation of targeted bacterial genetic segments into the 
phage genome, which often confers a beneficial trait to the phage 98. In both cases, the newly 
introduced bacterial genetic material could result in the existing prophage blocking another 
temperate phage from infecting that same bacterial host. This phenomenon is known as 
superinfection immunity 153,154, and is facilitated by a prophage-encoded repressor, which 
inhibits the expression of the newly introduced phage nucleic acid material 70–72,86,155. In rare 
cases, this can convert a phage sensitive bacterium into an insensitive one and might reduce 
the efficacy of phages as therapeutics. As new phages are being discovered and characterized, 
more research should focus on ensuring that phages undergoing superinfection immunity are 
avoided at all cost and should not be used in clinical settings for therapeutic purposes. 
 
1.11 Hypothesis 
 
While UTIs continue to be such a common and recurrent infections in humans, the increase 
in multi-drug resistant UPEC strains is alarming as this poses a major threat to public health 
4,156. Use of phages, with or without antibiotics, to treat drug resistant bacterial infections 
offers a promising alternative or adjunctive treatment to antibiotics for UTIs. The success of 
using phages in certain eastern European countries for clinical treatment of antibiotic 
resistant infections and their current use as a food additive in bio-control suggests this avenue 
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of microbial control should be researched more aggressively 
 
This study hypothesized that lytic phages will be present in environmental samples that are 
likely to contain E. coli (such as cow, goat, sheep faeces, river water, sewage), and these will 
then be used to target UPEC strains and may later have the potential to be developed for 
phage therapy. 
 
1.12 Rationale 
 
Phages require bacterial hosts for survival hence they are more abundant where their hosts 
are highly concentrated 157. E. coli is a common commensal of the human and animal 
gastrointestinal tract (GIT). As a result, E. coli will commonly be excreted into the 
environment, including soil, sewage, rivers, dams and oceans. Lytic phages against UPEC 
strains should be found in abundance in environments where their host prevails. 
 
1.13 Aim of this study 
 
To isolate and characterize virulent phages from the environment that target uropathogenic 
E. coli strains. 
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1.14 Objectives of the study 
 
Specific objective 1: To screen a panel of environmental samples for the presence of lytic 
phages against E. coli laboratory strain K-12 MG1655. 
 
Specific objective 2: To determine the host range of the purified E. coli K-12 MG1655-specific 
phages against a panel of clinical strains of UTI E. coli from the E. coli reference collection 
(ECOR). 
 
Specific objective 3: To phenotypically and genotypically characterize pure phage isolates that 
are lytic against UPEC strains using electron microscopy, restriction mapping and sequencing. 
 
 
 
 
2 MATERIALS AND METHODS 
 
 
2.1 Culture media 
 
 
The reagents and culture media constituents used in the study were purchased from Sigma 
Aldrich (St. Louis Missouri, USA) unless otherwise stated. Luria Bertani (LB) media 
(containing 10g/L Tryptone, 10g/L NaCl and 5g/L yeast extract, pH 7.2), supplemented with 
10mM CaCl2 and 10mM Maltose/MgSO4 was used to culture E. coli strains and for phage 
plaque/spot assay. 
 
 
 
 
2.2 Bacterial strains and culture conditions 
 
 
Eleven UPEC strains from ECOR, the E. coli reference collection (Table 2.1; kindly provided by 
Dr. Rémy Froissart, from the French National Research for Scientific Research [CNRS], 
Montpellier, France), were selected from 72 reference strains which have been well described 
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and used in previous published studies, by Ochman H. and Selander 54 and Herzer P.J.55. All 
selected UPEC strains were isolated from urine samples of patients with clinical UTIs from 
varying geographical locations in Sweden. The ECOR strains represent a spectrum of 
genotypic variants of E. coli. In addition, the laboratory strain E coli K-12 MG1655 which 
is known to be susceptible to a number of different of phages,158 was included as a 
propagating strain and a positive control. The E. coli strains were cultured aerobically 
[constant agitation at 120 rpm using a shaking incubator, (model FSM-SPO, Labcon)] at 370C 
overnight. Following an overnight culture, the cultured strains were frozen in 20% glycerol 
(v/v) at -800C until further use. 
 
Table 2.1: UPEC standard reference strains included from the ECOR collection 
 
Strain No. Previous Designation Phylogenetic group 
ECOR-11 C97 A 
ECOR-14 P62 A 
ECOR-40 P60 D 
ECOR-48 C90 D 
ECOR-50 P97 D 
ECOR-56 P106 B2 
ECOR-60 C89 B2 
ECOR-62 P69 B2 
ECOR-64 C70 B2 
ECOR-71 ABU84 B1 
ECOR-72 P68 B1 
Table adapted from Ochman H. 54 and Herzer P.J. 55. The phylogenetic allocation of the ECOR strains into their respective 
groups was derived using the NJ algorithmic method which compares the genetic distances of the 38 enzyme loci of 
these strains, based on polymorphisms. 
 
 
2.3 Collection and processing of environmental samples 
 
Environmental samples were collected from different locations in Cape Town, South Africa 
into sterile 50ml Falcon tubes using a sterile spatula (Sterile Cellstar, Sigma Aldrich, USA) for 
solid samples and Pasteur pipette for liquid samples (Sterile Cellstar, Sigma Aldrich, USA). 
Each tube was labeled with the description of content and the location at which the sample 
was collected. Samples were then transported at room temperature to the laboratory and 
stored at 40C until they were processed. SM buffer [100mM NaCl, 10mM MgSO4•7H2O, 50mM 
Tris-HCl (pH 7.4)] was added to the solid and semi-solid samples in a 1:1 ratio and mixed 
thoroughly, while liquid samples were processed without SM buffer. Samples were 
centrifuged at 2465 g (Eppendorf 5810 centrifuge) for 30 minutes to remove any particulate 
22  
matter. The supernatant was added to a new 50ml tube (Sterile Cellstar, Sigma Aldrich, USA) 
and 10% v/v chloroform (Sigma Aldrich, USA) was added to remove residual bacterial debris 
and inverted 10 times. Finally, the samples were centrifuged at 1258 g for 10 min followed by 
harvesting the chloroform-free supernatant and transferred to a new 50ml tube and stored 
at 40C until further use. 
 
2.4 Bacteriophage enrichment and isolation 
 
To amplify phages from the environmental samples, 100 l of the supernatant was added to 
4.9 ml E. coli K-12 MG1655 overnight culture at an OD600nm of 0.3-0.4. The mixture of E. coli 
and environmental samples were incubated for 15 min at 370C without shaking and then 
overnight at 370C under aerobic conditions, shaking at 120 rpm. The enriched phage-E. coli 
cultures were stored at 40C for an hour and then centrifuged at 2465 g for 30 min. Chloroform 
(10%v/v) was added to the supernatant and centrifugation progressed at 1258 g for 10min. 
The chloroform-free supernatant was transferred to two Eppendorf tubes and stored at 40C 
until needed. 
 
E. coli K-12 MG1655 was used to purify single plaques from serially diluted phage 
concentrates using the double layer plaque assay as follows; 20ml of LB agar (1.2%) was 
poured onto petri dishes and allowed to set as bottom agar at room temperature for 15 
minutes. Soft overlay LB agar (0.6% agar; 4ml) was added to 15ml tubes and maintained 
at 450C in a heating block (AccublockTM Digital dry bath, Labnet). The phage concentrates 
and the overnight E. coli K-12 MG1655 culture were mixed in a 1:1 ratio (200µL each) and 
added to the soft overlay agar, then mixed gently using a vortex mixer. This mixture was 
poured over the bottom agar and allowed to set. Plates were incubated at 370C overnight. 
Plaques were identified by the appearance of clear zones on the bacterial lawn, which 
indicated bacterial lysis by phages. The plaques were isolated based on their 
morphologies, which includes different sizes (small, medium or large), characteristics of the 
zone clearance (turbid or clear), and shape of the plaque (circular or irregular). Phages 
were selected from plaques with varying size and shape although all picked plaques were 
clear. To increase the likelihood that one type of phage was picked per plaque and to 
decrease the likelihood of identical phages 
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being propagated from environmental sources, the plaque assay was repeated at least three 
times. 
 
2.5 Characterization of phage host range against UPEC isolates 
 
To determine whether the isolated phages will be lytic to more than one UPEC strain, an 
agar assay was carried out in which the susceptibility of different UPEC strains to the 
isolated phages was tested. Twenty milliliters of LB agar (1.2%) was poured onto petri 
dishes and allowed to set as before. Ten microliters of the bacteria-free phage supernatant 
were aliquoted to the LB agar plates inoculated with different UPEC isolates. The plates 
were incubated overnight at 370C and inspected for the presence of plaques. 
 
 
2.6 Purification of phages for transmission electron microscopy (TEM) 
 
Two methods were employed for the purification of phages: (1) the first method used PEG 
8000 (10% wt/vol) and NaCl (1 M final). The tubes were inverted 3 times and kept at 
40C overnight 100K and centrifuged for 2 h at 15 000g, 40C (Sorval RC 5C plus, Labnet). 
The supernatant fraction was discarded, and the pellet was resuspended in 1ml of SM 
buffer. The phage suspensions were aliquoted into Eppendorf tubes a day later and 
stored at 40C for further analysis. (2) The second method used Chloroform (10% v/v), 
which was added to the phage suspension and vortexed vigorously followed by 5 
minutes of room temperature incubation. This procedure was repeated twice. The phage 
suspension with the chloroform were centrifuged for 10 min at 16 000g (Eppendorf 5810R 
centrifuge) at 40C. The upper layer containing the phages was recovered without 
disturbing the interface and transferred to a new 50ml tube. The phage suspension was 
filtered through 0.2 m filter and stored at 40C until further use. To increase the phage 
titer, a large volume of phage sample was used (4 X 1.5ml Eppendorf tubes per sample). 
The phages were pelleted for 1 h at 20 800g at 40C. Without disturbing the pellet, the 
supernatant was discarded, and the phages were resuspended in 100 l of TEM 
buffer [0.1 M NH4-acetate; pH 7.0]. All the content of the Eppendorf tubes was pooled 
together in a single 2 ml Eppendorf tube for each of the phage isolates and TEM buffer was 
added to fill the Eppendorf tube. This washing step was repeated twice. The final 
resuspension volume was 100 l of TEM buffer and the phages were stored at 40C until 
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visualized by TEM. 
 
Prior to doing TEM, phage concentrations (plaque forming units [PFU]/ml) were determined 
for each isolate (Table 2.2). This was done to ensure that sufficient quantities of each phage 
are utilized to optimize their recovery under the microscope. To carry this out, a spot assay 
was conducted with 10l of each phage suspension at the following dilutions; 100, 10-2, 
10-4, 10-6, 10-8 and 10-10 on a lawn of E. coli MG1655. If a phage could not form a plaque at 
a dilution of <10-6 then   8 X1.5 ml tubes of each phage sample were purified using 
chloroform and centrifuged, then 
then the recovered phage lysate was viewed on TEM. If a phage could form plaques at a 
dilution of 10-6 then 4 x 1.5 ml Eppendorf tubes were purified for that sample and the 
recovered phage lysate was viewed on TEM. The rationale was that, phages not being able 
to form plaques at <10-6 had a very low titer which would not allow for visualization under 
the microscope hence the titer had to be increased by increasing the number of tubes which 
consequently led to an increase in phage volume.                                                 
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Table 2.2: Titration of phages in each sample for TEM analysis 
 
Plaque formation per dilution 
 10-0 10-2 10-4 10-6 10-8 10-10 
Phage ID       
16-1 − − − − − − 
16-2 − − − − − − 
16-3 − − − − − − 
16-4 − − − − − − 
16-5 − − − − − − 
16-6 − − − − − − 
16-7 − − − − − − 
16-8 + + + + − − 
16-9 + + + + − − 
16-10 + + + + − − 
16-11 + + + + − − 
16-12 + + + + − − 
16-13 + + + + − − 
16-14 + + + + − − 
16-15 + + + + − − 
16-16 + + + + + − 
16-17 + + + + − − 
16-18 + + + + − − 
17-1 + + + + + − 
17-2 + + + + + − 
17-3 + + + + + − 
17-4 + + + + + + 
17-5 + + + + + − 
17-6 + + + + + − 
17-7 + + + + + − 
17-8 + + + + + − 
17-9 + + + + + − 
17-10 + + + + + − 
17-11 + + + + + − 
17-12 + + + + + − 
17-13 + + + + + − 
NOTE: Phages are indicated on the y-axis from 16-1 to 16-18 for those isolated in 2016 and 17-1 to 17-13 for those isolated in 2017. Plaque 
formation 
is indicated “+” and no plaque formation is indicated with “−”. 
 
 
2.7 Characterizing phage morphology by TEM 
 
 
The purified phage particles were transported in TEM buffer at 40C to the Center for Imaging 
and Analysis, housing the Electron Microscope Unit, University of Cape Town. To visualize 
phages by TEM, 10 l of each phage suspension was pipetted on parafilm and carbon coated 
copper grids (Agar Scientific, UK), which were glow discharged using an EMS100 Glow 
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Discharge Unit (Electron Microscopy Sciences, USA) in order to create a hydrophilic effect on 
the coppers surface. The phage samples were coated onto the grids for 10 min. Grids were 
washed twice with distilled sterile water and were negatively stained by 2% uranyl acetate 
(SPI Supplies, USA). The phage preparations were visualized under the supervision of Dr 
Mohammed Jaffer (UCT Electron Microscope Unit), using a FEI Tecnai 20 transmission 
electron microscope (FEI, Eindhoven, Netherlands), operating at 200 kV (Lab6 emitter) and 
fitted with a Tridiem energy filter and Gatan CCD camera (Gatan, UK). Phages were classified 
to recognized phage families according to their respective tail length, tail width and capsid 
diameter, as described in Table 2.3. 
Table 2.3: Summary of characteristics by which phages will be grouped 
 
Phage 
Families 
Phage Morphologies Nucleic Acid 
Type 
Size Lifecycle Shape Genome Sizes 
Myoviridae 
 
DS linear DNA Capsid 50- 
110nm 
Tail <114 nm 
Virulent Hexagonal head rigid 
tail with a contractile 
sheath and tail fibers 
33-244kB 
Siphoviridae 
 
DS linear DNA Capsid 60nm 
Tail 150x10nm 
Temperate or 
Virulent 
Hexagonal head, with a 
flexible/contractile tail 
and may/may not 
contain tail fibers 
35 - 70kb 
Podoviridae 
 
DS linear DNA Capsid <60nm 
Tail <17nm 
Virulent Hexagonal head and a 
non-contractile tail 
shorter than their 
head 
40-42kb 
Inoviridae 
 
 SS circular DNA Length 700nm- 
2000nm 
Diameter 
6-10nm 
Temperate Long and filamentous 
rod like shape 
4.5-8kb 
Rudiviridae  
 
DS linear DNA Length 600- 
900nm 
 
23nm in width 
Neither 
temperate nor 
virulent; Chronic 
Rigid, thick rods 24 – 35kb 
Table was adapted from Ackerman (2007) with minor modifications. 
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2.8 Bacteriophage DNA extraction 
 
A high titer lysate (10-6 PFU/ml) was generated for all the phage isolates using the E. coli K- 
12 MG1655 strain to ensure optimal DNA yield. To extract phage DNA, two methods were 
employed: 
 
1. The first method used phenol-chloroform-isoamyl alcohol (25:24:1). To maximize 
the DNA yield, the volume of each sample was increased by using 12-30 Eppendorf 
tubes depending on the phage titer of each sample, with more tubes being required 
if the number of phages were low (determined by calculating the PFU/ml). The phages 
were washed by pelleting them for 1 h at 20 800g at 40C. The supernatant was 
discarded, and pellets were resuspended in 100 l of buffer containing 100mM Tris-
HCl, 25 mM MgCl2 (pH 7.5), and 1M NaCl (buffer A). All the contents of the Eppendorf 
tubes were pooled into a single 2 ml Eppendorf tube for the respective phages and 
filled with buffer A. This washing step was repeated once. To avoid host 
genomic DNA contamination, 10 l of DNAse I (11U/l), 5 l of RNAse I (4 g/l) 
and 1 l of DpnI (1X) SuRE/Cut buffer M was added to the respective phage 
suspensions and incubated at 370C for 1 h without agitation. Following digestion, 
each tube was filled with buffer containing 100mM Tris-HCl, 25 mM MgCl2 (pH 7.5) 
(buffer B). To wash the phages, suspensions were pelleted for 1 h at 20 800g at 
40C. The pellets were washed with buffer B as before. This washing step was 
repeated once more, and the pellets were resuspended in 800 l of buffer B and 
transferred to 2ml Eppendorf tubes. DNA was purified by adding the 
Phenol/Chloroform/Isoamyl alcohol mixture to the phage suspensions, 
vortexing, and then centrifuging for 10 min at 16 000g at 40C. Without disturbing 
the interface, the upper aqueous layer was transferred to a clean 2 ml Eppendorf 
tube and this process was repeated twice. The final elution was centrifuged for 10 min 
at 16 000g at 40C. The supernatant containing DNA was harvested and divided 
equally into two new 1.5ml Eppendorf tubes. Next, 2.5 x the DNA eluent volume 
of absolute ethanol (99% final) (Sigma Aldrich, USA) was added, in addition to 
0.1 x volume of 3M Sodium-acetate. This suspension was vortexed and stored at -200C 
overnight. The sample was then centrifuged for 30 min at 20 800g at 40C. The 
supernatant was discarded and 1ml of 70% ethanol was added, without disturbing the 
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pellet and centrifuged. The supernatant fraction was then carefully removed without 
disturbing the pellet and the tubes were left to dry on the bench to allow the ethanol 
to evaporate. The DNA pellet was resuspended in 50 l of nuclease free water and 
stored at 200C for further use. 
 
2. The second method used a Phage DNA Isolation Kit (Norgen Biotek Corp, Canada). 
Host genomic DNA was degraded using DNAse I (2U/l), followed by DNAse 
I inactivation at 750C for 5 minutes. Five-hundred microliters of lysis buffer was 
added to the phage DNA elution and vortexed vigorously for 10 seconds. To increase 
the DNA yield, 4l of 20mg/ml proteinase K was added and incubated at 550C for 30 
min. The lysate was incubated at 650C for 15 min, inverting the tube continuously 
during the incubation period to ensure that the solution is homogenous before 
applying it to the spin column. Isopropanol (320l) was then added and mixed 
briefly. Then, 650 l of the lysate was applied to the spin column and centrifuged 
at 6 000g for 1 min. The flow-through was discarded. To ensure that the entire 
lysate passed through the column, the binding step was repeated until the entire 
sample had passed through. The column was washed with 400 l of wash solution 
A (provided with the kit) and centrifugation proceeded as before. The flow-through 
was discarded. The washing step was repeated twice. The column was centrifuged 
at 14 000g for 2 min to dry the column and ensure that all wash buffers are removed. 
To elute the DNA, the column was placed into a fresh 1.7ml elution tube and 700 l 
of elution buffer (provided with the kit) was added. The column was centrifuged 
as before. The elution step was repeated once using a separate elution tube. 
 
 
2.9 Genome fingerprinting using restriction fragment length polymorphism 
 
To determine the genetic diversity of the individual phages, digestion was conducted on 
phage DNA purified with DNA isolation kit as the DNA concentrations isolated using the 
phenol-chloroform method was either too low or had poor quality to be visualized on a gel 
hence it was excluded from further analysis (data not shown). Their DNA was digested with 
restriction enzyme HaeIII (Roche Diagnostics GmbH, Germany) according to the 
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manufacturer’s recommendations. HaeIII recognizes 5’-GG/CC-3’, and cleaves between G 
and C 159,160. Briefly, one unit of HaeIII that can cleave 1 g of DNA at +370C for 1hr 1 h in 
a final volume of 25 l (1X) SuRE/Cut buffer M was added to the DNA. Following incubation, 
the digestion mixture was immediately run for 1 hour at 100V on a 0.8-1% agarose gel in 
TAE buffer at pH 8.0 (Thermo Fisher Scientific company, USA). Undigested genomic DNA was 
used as a negative control whereas Lambda phage DNA was used as a positive control. On 
each gel, a GENERULER 1kb DNA ladder (Thermo Fisher Scientific Company, USA) was 
included. The gel was stained with Gel Red (Roche Diagnostics GmbH, Germany). 
 
3 RESULTS 
 
3.1 Isolation of phages from environmental samples 
 
Between 2016-2017, environmental samples were collected from 31 different sources 
(animal faeces raw milk, mud, river, pond and dam water, organic fertilizer, compost heap) 
at seven different locations around Cape Town, South Africa (Table 3.1). Sampling locations 
were selected because E. coli is from faecal samples and sewage waste are occasionally 
deposited into soil and water associated areas 14. Twelve of these 31 samples were in solid 
form (including faeces and fertilizer), 8 were in a semi-solid (including mud and sludge), and 
11 were liquid (including effluent and water from various nearby rivers and dams). Although 
all samples were screened for phages, a total of 41 phages were isolated from only six of these 
samples, including mud from the Liesbeeck River collected in Rondebosch; goat faeces and 
raw milk collected from Skaapkraal farm, Ottery; dam and pond water from Dreyersdal farm, 
Bergvliet). This suggested that E. coli phages were more likely to be found in samples with 
high water content, although not all semi-solid or liquid samples contained phages. 
 
Each of these environmental samples were tested against E. coli K-12 MG1655 15,161. Since 
different phages form plaques of different morphotypes, individual plaques with diverse 
morphotypes were selected from each sample. Only clear plaques were collected for further 
evaluation since those that were turbid could indicate the presence of temperate phages 123. 
Plaques with an irregular shape, even if clear, were excluded. Figure 3.1 shows a series of 
representative phage plaques on a lawn of E. coli MG1655.                                       
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Table 3.1: Screening of environmental samples for lytic phages against E. coli  MG1655 
 
Sample location 
(GPS coordinates) 
Sample type Nature of 
sample 
Number of phages 
isolated 
Liesbeeck River, Rondebosch 
(33.9658° S, 18.4810° E) 
Bird faeces Solid 0 
Mud by Liesbeeck Road Semi-Solid 0 
 Liesbeeck River Mud Semi-Solid 5 
 Water from Liesbeeck river Liquid 0 
Observatory 
(33.9376° S, 18.4721° E) 
Organic Fertilizer Solid 0 
Skaapkraal Farm, Ottery 
(34.0112° S, 18.5092° E) 
Cow faeces Semi-Solid 0 
Horse faeces Semi-Solid 0 
 Sheep faeces Solid 0 
 Goat faeces Solid 6 
 Duck faeces Solid 0 
 Dam Water liquid 0 
 Mud (by the dam) Semi-Solid 0 
 Sheep faeces Solid 0 
 Raw Milk Liquid 7 
Qurbaan Farm, Ottery 
(34.0112° S, 18.5092° E) 
Horse faeces Semi-Solid 0 
Sheep faeces Solid 0 
 Mud (from the sheep pen) Semi-Solid 0 
Master Organics Compost Supplier; 
(34°02 51.8’’S18°31’42.4’’E) 
Cow faeces 1 (deep layer) Solid 0 
Cow faeces 2 (superficial layer) Solid 0 
 Compost Heap Solid 0 
 Cow faeces 3 (superficial layer) Solid 0 
 Cow faeces 4 (superficial layer) Solid 0 
 Water from stagnant Pond Liquid 0 
Dreyersdal Farm, Bergvliet 
(34°03’21” S18°27’22” E) 
 
Water from stagnant Pond (site a) 
 
Liquid 
 
4 
  
Water from stagnant Pond (site b) 
 
Liquid 
 
4 
  
Dam Water 
 
Liquid 
 
15 
Athlone Water Treatment Works 
(33.9653° S, 18.5018° E) 
Primary sedimentation tank overflowa Liquid 0 
Primary sludgeb Semi-solid 0 
 Mixed liquorc Liquid 0 
 Final effluent d Liquid 0 
 Vygieskraal rivere Liquid 0 
aPrimary sedimentation tank liquid overflow was pre-treated overflowing wastewater without biological solids; bPrimary Sludge   was settled 
sludge, following primary treatment of sewage; cMixed Liquor was wastewater and raw biological mass; dFinal effluent was treated wastewater 
flowing out of treatment plant into the Vygieskraal River in Athlone; eVygieskraal Riverwater, Athlone was river water upstream of the Water 
Treament works that neighbours the plant, into which processed effluent is drained 
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Figure 3.1: Plaque morphology of coliphages on an E. coli MG1655 lawn, from (B) Raw milk 
from Skaapkraal Farm, (C) goat faeces from Skaapkraal Farm, and (D) river mud from 
Liesbeeck River and a negative control (A). Shown in black circles are their different sizes 
(small, medium or large), circular shape and clear plaques that were chosen. Images were 
taken using Panasonic DMC-TZ8 camera. 
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3.2 Identification of phages lytic to UPEC strains 
 
The isolated 41 phages were tested for their host range against the 11 UPEC strains from the 
ECOR collection (listed on Table 2.1). Figure 3.2 shows representative plaques formed by 
phages 16-1 to 16-5 that were lytic on ECOR 40 and phages 16-10 to 16-13 on ECOR-50. Only 
clear and round plaques were acknowledged for further evaluation. Plaques formed against 
E. coli MG1655 were generally clearer than plaques against the UPEC strains. Furthermore, 
the sizes of the plaques varied against each E. coli strain, with plaques formed against E. coli 
MG1655 tending to be larger than those against UPEC strains. Phages 16-1 to 16-7 isolated 
from raw milk from Skaapkraal Farm, 16-8 to 16-13 isolated from goat faeces collected at 
Skaapkraal Farm, and 16-14 to 16-18 isolated from the Liesbeeck River mud yielded larger 
plaques against E. coli MG1655 than any of the UPEC strains, and all these phages could 
infect at least one UPEC strain. 
 
Not all of the 41 isolated phages could lyse the UPEC strains. Only 31/41 (76%) of the phages 
that were isolated could infect UPEC strains, and only 7/11 (64%) of the UPEC strains were 
susceptible to  phage lysis (Table 3.2). It is important to note that since a 1/3 of  these phage 
samples were contaminated, their host range could have been altered and thus  Table 
3.2 might not be a true reflection of the activity of theses phages. The, four phages 
isolated from Skaapkraal raw milk (16-3, 16-4, 16-5 and 16-7) had the broadest host range, 
being lytic against 4/11 (36%) UPEC strains. Five phages isolated from dam water or a 
stagnant pond at Dreyersdal Farm infected only one UPEC strain: ECOR-72. Of the 11 UPEC 
strains, ECOR-72 was determined to be the third most susceptible to phage lysis in this study, 
following ECOR-50 and ECOR-40 (Table 3.2). Four of the UPEC strains, including ECOR-14, 
ECOR-60, ECOR-62 and ECOR-64 were not susceptible to any of the phages tested (Table 
3.2). The phages isolated in this study had a relatively narrow host range, suggesting that 
they would make good candidates for use in phage therapy. 
 
The similarity in host range lysis profiles seen for some phages suggests that they could 
possibly be either identical phages or closely related (Table 3.2). Phages 16-1 and 16-2 were 
both isolated from raw milk from the same farm, and both infected UPEC strains ECOR-11, 
- 40 and -50. Similarly, phages 16-3, 16-4, and 16-5 (also all isolated from raw milk) all 
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infected UPEC strains ECOR-11, -40, -48 and -50. Phages 16-8 and 16-9, both isolated 
from goat faeces collected at Skaapkraal Farm, infected UPEC strains ECOR-40, -50 and -71. 
Phages 16- 10, -11, -12, and -13, also isolated from goat faeces from the same farm, all 
infected UPEC strains ECOR-40 and 50. Phages 16-14, -15, -16, -17 and -18, all isolated 
from mud collected form the Liesbeeck River, also had a similar infectivity pattern that was 
seen for phages 16- 10 to 16-13. Similarly, phages 17-1, -2, -3, -4, -5, -8, -9 and -11, all 
isolated from Dreyersdal Dam water, all caused lysis of UPEC strains ECOR-56 and ECOR-
72. Phages 17-6, -7, -11, -12 and -13, which were all isolated from Dreyersdal dam 
water or pond water at the same location, all infected only ECOR-72. Two phages (16-6 
ad 16-7) isolated from raw milk, had infectivity pattern that was not similar to any of the 
other host range patterns generated by these phage isolates, which implies that they are 
not identical nor closely related to any of the other phages isolated from Skaapkraal raw 
milk. 
Since only 31 of the 41 phages isolated in this study could infect at least one of the UPEC 
strains, subsequent characterization of the morphology of only these 31 strains was 
performed. Overall, phages from this study generally had narrow host ranges (infecting a 
median of 4 of the UPEC strains screened). This finding is advantageous in phage therapy 
because only specific bacterial strains could be targeted and in the case of attempting to 
widen phage host range, different phages could be combined to increase their bacterial 
targets116.  Furthermore, phages isolated from the same samples had a tendency of 
having similar UPEC host ranges, suggesting that they were related genetically. In the 
event that they were genetically different, it’s possible that they had common receptors 
hence making them display similar host ranges. This data also suggests that UPEC strains 
may also exist in nature since phages targeting UPEC strains were isolated. 
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Figure 3.2: Comparison of plaque morphology against E. coli MG1655. (A and C) or UPEC 
strains ECOR-40 and ECOR-50 (B and D) for phages 16-1 to 16-5 (isolated from raw milk) 
and phages 16-10 to 16-13 (isolated from goat faeces). Images were taken using Panasonic 
DMC- TZ8 camera. 
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Table 3.2: Host range testing of isolated coliphages against 11 UPEC strains 
 
 
 
 
 
Sample 
location 
 
 
Phage 
isolates 
      UPEC Strains       
40 50 72 56  11 71 48 14 60 62 64 
Lytic 
activity 
(%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Susceptibility 
of UPEC 
strains to 
phages 
(%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 55 42 26 23 13 10 0 0 0 0                                
 
 
 
 
 
 
Raw milk 16-3 + + + + 36 
 16-4 + + + + 36 
 16-5 + + + + 36 
 16-7 + + + + 36 
 16-1 + + +  27 
 16-2 + + +  27 
 16-6 +  + + 27 
Goat manure 16-8 + +  + 27 
 16-9 + +  + 27 
 16-10 + +   18 
 16-11 + +   18 
 16-12 + +   18 
 16-13 + +   18 
River mud 16-14 + +   18 
 16-15 + +   18 
 16-16 + +   18 
 16-17 + +   18 
 16-18 + +   18 
Dam water 17-1  + +  18 
 17-2  + +  18 
 17-3  + +  18 
 17-4  + +  18 
 17-5  + +  18 
 17-8  + +  18 
 17-9  + +  18 
 17-11  + +  18 
 17-6  +   9 
 17-7  +   9 
 17-10  +   9 
Pond water 
(site a &b) 
17-12  +   9 
17-13  +   9 
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The different colors indicate coliphages that infected similar UPEC strain ranges. Plaque formation is indicated with “+”. 
 
 
 
3.3 Coliphage phenotype by TEM 
 
To further characterize the 31 phages that were lytic to UPEC strains, their morphologies 
were determined using electron microscopy. From these 31 phages that were isolated from 
local environmental samples, 28/31 appeared to belong to one of the four major phage 
families, including Myoviridae (representative images shown in Figure 3.3), 
Siphoviridae                                                                                                      
 (representative images shown in Figure 3.4), Inoviridae (representative images shown 
in Figure 3.5) and Rudiviridae (representative images shown in Figure 3.6). Three phages 
that were isolated (including 16-14, 17-12a and 17-13) could not be categorized, as 
their dimensions did not match any of the phage families previously described 
(representative images shown in Figure 3.7). In addition, 12/31 samples appeared to 
contain mixtures of different phage populations, despite several rounds of serial purification 
being carried out for each of the phage preparations (including phage samples 16-12, -15, -
16, -17, 18 and 17-5, - 
6, -3, -7, -9, -11 and -12, Table 3.3) (representative images shown in Figures 6, 7, 8 and 
9). Phage samples with mixed populations are designated with either letter a or b next to 
the phage ID (Table 3.3). 
 
 
 
The majority of the phages that were isolated were tailed, with either icosahedral or round 
heads, most probably belonging to the family Myoviridae or Siphoviridae. A total of 16/31 
(52%) samples contained phages belonging to the Myoviridae family. These phages had rigid, 
contractile tails with fibers (usually 6 tangled fibers) at the one end spread apart (sample 16- 
1; Figure 3.3). The fibers were seen on phages isolated from raw milk, goat faeces and river 
mud. Samples 17-5a and 17-6a (Figure 3.3), isolated from Dreyersdal dam water did not 
contain fibers. Unlike Siphoviridae phages, the presence of fibers is common amongst 
Myoviridae phages. However, the absence of fibers in these two phages could have been a 
result of them being lost through mechanical damage during purification. Although not seen 
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in any of the phages isolated in this study, Myoviridae phages commonly have a collar with 
short spikes emerging from the base plates around collar. The length of Myoviridae phages 
isolated in this study ranged between 103nm to 127nm, with a mean tail width of 13 nm 
(standard deviation [SD] ±  0nm) and a mean capsid diameter of 72nm (± 4) (Table 3.2).     
 
 
 
 
 
Figure 3.3: Electron micrographs of coliphages with a structural resemblance of phages 
belonging to the Myoviridae family. Phage images of contaminated samples are indicated with “a”. 
Images were taken using a FEI Tecnai 20 TEM operating at 200K at a magnification of 
100K. 
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The second largest group of phages isolated was assigned to the Siphoviridae family as a result 
of their long thin, non-contractile tails ranging from 116nm to 170nm in length and 11 (± 0.5) 
to 22± 27 nm in width. In general, Siphoviridae phages tend to acquire an S-spiral 
morphology which has been suggested to be a result of an artefact resulting from EM 
preparation162. Samples 17-1, 17-2, 17-3, 17-7a, 17-8, 17-9a, 17-10, 17-11a and 17-13a 
(Figure 3.4) all had phages with a spiral morphology and that clumped together possibly 
as a result of a high phage titer. Samples 16-7 and 16-13 have a similar structure with tails 
of almost size (1nm difference between the tail length and width) suggesting that they could 
be the same kind of phage although they were isolated from different sources, raw milk 
and goat faeces. Although there is an overlap between Myoviridae and Siphoviridae 
phages, what distinguishes the two families is the presence of a neck found in 
Myoviridae phages connecting the tail to the capsid, the rigidity of tails found in Myoviridae 
phages compared to the flexible thin tails of Siphoviridae phages. Moreover, Siphoviridae 
phages tend to have round and smaller capsids (>60nm), compared to Myoviridae phages 
which have been shown to encapsulate large DNA material due to their enormous capsids that 
can go up to 110nm in diameter and the phage particles are generally more heavier163. 
Myoviridae and Siphoviridae may appear similar due to some structural similarities hence 
careful analysis is required to distinguish them. 
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Figure 3.4: Electron micrographs of coliphages with a structural resemblance of phages 
belonging to the Siphoviridae family. Phage images of contaminated samples are indicated with “a”.  Red 
arrows indicated possible mixed phage populations and the phage(s) that were measured 
Images were taken using a FEI Tecnai 20 TEM operating at 200K at a magnification of 
100K. 
 
 
Phages belonging to the families Inoviridae and Rudiviridae were the two main culprits in co- 
existing with phage of other families in samples of “mixed” populations. Inoviridae phages, 
known for their long, flexible and filamentous rod-like structures were found to co-exist with 
four Siphoviridae phages (17-3b,17-7b,17-9b and 17-11b; Figure 3.5) and thee 
Myoviridae phages (including samples 16-16b,16-17b and 16-18b; Figure 3.5).Three samples 
(16-11,16- 12b and 16-15b; Figure 3.5), isolated from goat faeces and Liesbeeck River 
water, only contained filamentous phages that belonged to the family Inoviridae. All the 
phages found to belong to the family Inoviridae were fd type phages which are filamentous 
and long (up to 2000nm in length) as opposed to MV-L1 type phages which are known 
for their short rod nature that has one oval end and another end which can acquire 
different shapes92,94. 
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Figure 3.5: Electron micrographs of coliphages with a structural resemblance of phages 
belonging to the Inoviridae family. Phage images of contaminated samples are indicated with “a” and 
“b”. Red arrows indicated possible mixed phage populations and the phage(s) that were 
measured Images were taken using a FEI Tecnai 20 TEM operating at 200K at a 
magnification of 100K. 
 
 
Three samples contained phages belonging to the family Rudiviridae (Figure 3.6). These 
phages were found to be associated with two samples containing Myoviridae phages 
(including samples 17-5b and 17-6b; Figure 3.6) and one sample containing phages that could 
not be identified (including samples 17-12b; Figure 3.6). Although they both consist of rod- 
shaped phages, Inoviridae and Rudiviridae phages are different in that Rudiviridae phages are 
not flexible and are often shorter with a length ranging between 600nm-900nm and are at 
least 23nm wide. 
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Figure 3.6: Electron micrographs of coliphages with a structural resemblance of phages 
belonging to the Rudiviridae family. Phage images of contaminated samples are indicated with “b”.  Red 
arrows indicated possible mixed phage populations and the phage(s) that were measured. 
Images were taken using a FEI Tecnai 20 TEM operating at 200K at a magnification of 
100K. 
 
 
The next group of phages had dimensions that did not fit with any of the known phage families 
that have been described in the literature (Figure 3.3 to 3.6 and Table 2.3; Methods Section). 
Sample 16-14 (Figure 3.7) isolated from river mud harbored a phage with a round head and 
a diameter of 107nm resembling that of Myoviridae phages, however the length of the tail 
was too short belong to the family Siphoviridae nor Myoviridae but longer that the 
family Podoviridae hence indicating that the phage does not belong to any of the tailed 
phage families. The overall shape of the phage resembles that of the Podoviridae phages, 
with a large capsid and relatively short tail. Two samples (including 17-12a and 17-13; 
Figure 3.7) isolated from Pond Water (site b) each contained phages of similar structure, 
with capsids resembling those of Myoviridae phages except they are more elongated, 
however the diameter (79 ±  0.7 nm and 80 ±  3 nm; Table 3.3) mirrors that of Myoviridae 
phages which ranges between 50 nm to 110 nm. The tail size of phages from sample 16-
13 (116 nm x 18 nm; Table 3.3) resembles that of Myoviridae phages whereas the tail size 
of phages from sample 17-1 (131 ±  59 nm x 11 ±  0.5 nm) is challenging to be categorized 
since the standard deviation is very high, however taking the length of 131 nm into 
consideration without the standard deviation and the width size of 11 ±  0.5 nm, these 
phages would be assigned to Siphoviridae family. 
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Figure 3.7: Electron micrographs of unidentified coliphages. Phage image of contaminated samples 
is indicated with “a”. Red arrows indicated possible mixed phage populations and the 
phage(s) that were measured. Images were taken using a FEI Tecnai 20 TEM operating at 
200K at a magnification of 100K. 
 
 
The noise in the background of some micrographs could have been caused by residual 
bacterial debris resulting from lysate purification and could be reduced by increasing the 
purification steps of the phage lysates. Individual heads and tails were seen in some samples 
possible due to mechanical smearing that could have taken place during TEM preparation. 
Overall, phages isolated in this study were predominantly tailed with 39% of the samples 
consisting of mixed phage populations. As some most phages were observed to have similar 
structures, the possibility of genotypic variation exists thus this could be addressed through 
genotypic assays such as pulsed field gel electrophoresis, restriction fragment polymorphism 
or sequencing for accurate analysis. 
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Table 3.3: Morphological prediction of phage families 
 
Phage ID No. of phage 
particles 
measured 
Tail Length (nm) 
Mean (± SD) 
Tail Width (nm; 
mean ± SD) 
Capsid meter (nm; 
mean ± SD) 
Proposed Family 
16-1 1 103 19 89 Myoviridae 
16-2 1 118 20 86 
16-3 2 121 (± 9) 13 (± 0) 93 (± 0) 
16-4 12 114 (± 9) 17 (± 3) 83 (± 4) 
16-5 1 124 18 90 
16-6 1 127 19 96 
16-8 1 111 15 92 
16-9 1 117 20 89 
16-10 1 122 18 93 
16-12a 1 118 16 95 
16-15a 1 110 17 98 
16-16a 1 123 18 97 
16-17a 1 107 17 88 
16-18a 1 120 17 89 
17-5a 7 117 (± 5) 21 (± 3) 75 (± 5) 
17-6a 8 115 (± 6) 17 (± 3) 72 (± 4) 
16-7 1 117 16 73 Siphoviridae 
16-13 1 116 18 80 
17-1 4 131 (± 59) 11 (± 0.5) 65 (± 5) 
17-2 3 153 (± 8) 12 (± 3) 65 (± 1) 
17-3a 5 120 (± 19) 22 (± 27) 66 (± 6) 
17-4 5 149 (± 17) 13 (± 2) 63 (± 4) 
17-7a 6 148 (± 21) 12 (± 2) 63 (± 3) 
17-8 9 131 (± 26) 12 (± 3) 63 (±4) 
17-9a 2 170 12 65 
17-10 8 135 (± 24) 12 (± 2) 60 (± 4) 
17-11a 2 138 (± 43) 13 (± 3) 55 (± 3) 
16-11 1 580 7 None Inoviridae 
16-12b 1 1100 8 None 
16-15b 1 671 12 None 
16-16b 1 545 9 None 
16-17b 1 633 8 None 
16-18b 1 923 9 None 
17-3b 1 430 11 None 
17-7b 1 673 9 None 
17-9b 1 380 10 None 
17-11b 1 888 9 Non-existent 
17-5b 1 503 23 None Rudiviridae 
17-6b 1 367 30 None 
17-12b 1 350 30 None 
16-14 1 91 16 107 Unidentifiable 
17-12a 2 113 (± 2) 22 (± 1) 120 (± 1) 
17-13 6 112 (± 2) 20 (± 2) 121 (± 3) 
Italicized phage numbers are those with mixed populations evident; Alphabet “a” and “b” indicate phage 
micrographs taken from samples with mixed phage populations. 
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4 DISCUSSION 
 
 
UPEC strains are responsible for over 70% of UTIs worldwide,1 although, many of them have 
developed resistance to the antibiotics commonly used to treat them1,2. The emergence and 
spread of antibiotic resistance to this common human pathogen thus warrants urgent 
research into new treatments and effective ways to control it. Phage therapy, focusing on 
lytic phages against E. coli, is one such approach that could be useful in this setting. UPEC 
strains are a common resident of the human and animal GIT thus sewage water is often 
enriched with E. coli due to the presence of human and animal excreta164. In this greater 
context, this study aimed to isolate and characterize environmental virulent phages against 
UPEC strains. It was hypothesized that phages infecting UPEC strains could be found in 
environmental sources with high water content such as dams, rivers, river mud and/or animal 
faeces. Consequently, 31 environmental samples were screened for the presence of phages 
against UPEC strains and a total of 41 virulent phages that demonstrated the ability to lyse E. 
coli MG1655 were isolated. To determine their host range, these phages were then screened 
against a broader panel of UPEC strains of which 31/41 were lytic against these strains and as 
a result were further characterized morphologically using TEM. Based on morphology, 28/31 
isolates were determined to belong to four phage families whilst 3/31 isolates did not fit 
morphologically into any of the characterized phage groupings. Many phages were tailed, 
representing the phage families Myoviridae and Siphoviridae, while a fraction belonged to 
non-capsid phage families namely Inoviridae and Rudiviridae. 
 
4.1 Phage isolation and typing 
 
4.1.1 Environmental screening for phages lytic against E. coli MG1655 
 
 
A wide range of environmental samples, collected from seven different locations including 
Rondebosch, Observatory, Master Organics compost supplier, wastewater treatment plant, 
Skaapkraal, Qurbaan and Dreyersdal were screened for their presence of lytic phages against 
E. coli. The MG1655 strain of E. coli was used to propagate the phages in this first round of 
screening since it is considered highly susceptible to coliphages as a result of being “cured” of 
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integrated prophages and is uncomplicated to culture15,33. The MG1655 strain used in this 
study was specifically cured of the F-factor and lambda prophages using acridine orange 
and UV light respectively15. Of environmental samples that were screened, six out of 31 
were found to contain phages. Of these samples, dam water from Dreyersdal farm yielded 
the highest number of phage isolates (n=15/41 phages isolated), followed by raw milk 
(n=7/41), goat faeces (n=6/41) and river mud (n=5/41). The dam water sample from this 
study was isolated from a site were most animals from this farm including (ducks, cattle 
and goats) drink water from and farmers deposit sewage matter. This could have resulted 
in that large number of phage isolates from this sample since it is a potential dump site for 
multiple types of animal excreta and an end point for sewage hence increasing the chances 
of E. coli retrieval and the subsequent recovery of coliphages. A number of previous 
studies have recorded the presence of coliphages targeting WT E. coli K-12 strains from 
environmental water, wastewater treatment plant and lake water120,162,165. For instance an E. coli 
K-12 derivative, strain K803, devoid of prophages like the MG1655 strain used in this study, 
was used to isolate 22 T4 like phages from environmental water in Bangladesh128.T-4 like 
phages are notorious for their broad host range and are unequivocally abundant in 
nature122,126,128,166.This highlights the abundance of E. coli in water-associated ecosystems, 
confirming one of the assumptions made in this study that natural water sources contain bio- 
matter that allows for the growth and survival of E. coli strains. 
 
The second most abundant environmental sample screened for coliphages was raw cow milk, 
from Skaapkraal farm, Otterry, from which 7/41 phages were isolated. Although raw cow 
milk may contain E. coli167,168, coliphages were not expected from raw milk, as there have 
been no published studies that could be found reporting on isolation of E. coli-targeting 
phages from this source. However numerous studies have reported on the abundance and 
diversity of phages against Streptococcus spp. and Lactic acid-producing bacteria in raw 
milk167,169, commonly associated with manufacturing delays, production of a lower quality 
product, immature product spoilage or product loss altogether, leading to a significant 
economic loss in the dairy industry170. Since some phages have been reported to be polyvalent 
(defined as being able to infect more than one strain per bacterial species)166, and in some 
rarer instances can cross the bacterial species barrier, 145it is therefore possible for coliphages 
isolated from raw milk in this study to have a host range extending to lactic acid producing 
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bacteria and/or streptococcus that also infect E. coli MG1655 used to screen in this study. 
Since polyvalency is often witnessed in phages residing in marine-like environments and 
infecting the bacterial family Enterobacteriaceae of which E. coli is a member145 , it is thus 
possible for coliphages isolated from raw milk to also have that ability. Additionally, two 
coliphages AR1 and LG1 have been isolated from raw milk and were to infect two serotypes 
of E. coli and many other enterobacteria strains of different genera including Shigella 
dysenteriae, P. mirabilis and two strains of Salmonella171 . Another possibility would be that 
the raw milk from Schaapkraal farm could have contained E. coli, as E. coli is recognized as 
one of the most prevalent food-borne pathogens 172–174. A study conducted in Pakistan 
isolated E. coli from 57% of raw milk samples tested and 67% of household milk products 
sampled, using gram staining and culture techniques166. Another study undertaken in Mid- 
western Brazil screened 50 raw milk cheese samples using PCR for toxigenic E. coli and 96% 
of the samples were found to contain 48 different types of E. coli. Although several studies 
have reported the presence of toxigenic E. coli strains in raw milk, there is currently no 
evidence that any of E. coli commensal strains, specifically E. coli K-12 derivatives have been 
isolated from raw milk. However, considering that different E. coli serogroups do share 
common phage receptors (of which lam B175, OmpF, OmpC137, protein Ia, protein Ib176 have 
been best characterized), it is possible for phages infecting one serogroup to able to infect 
another serogroup. 
 
The environmental sample that yielded the third most abundant coliphages was goat faeces 
from Schaapkraal farm, Ottery, yielding 6/41 phage isolates. Since other farm animals, 
including cows, have been shown to harbor E. coli and coliphages in their GIT177–179, the 
presence of phages in any of the samples with animal faeces was not unexpected. Although 
there has been no published evidence that goat faeces harbors any of the E. coli K-12 
derivative strains, it has been established that sheep and goats are reservoirs of shiga-toxin 
producing E. coli (STEC) strains180,181 and more importantly STEC-specific phages131,180,182. As 
mentioned before that serogoups of gram-negative bacteria such as E. coli share 
phage receptors166,175,176, it is therefore possible that phages isolated from fecal samples 
of goat meant to originally target STEC could have been able to recognize some receptors 
on the surface of the MG1655 strain. It was surprising that only one sample out of 12 
containing animal excreta (goat faeces) contained coliphages, also suggesting that the 
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animals to which the samples belonged either did not harbor E. coli or coliphages, or that 
they were not viable 
 
The absence of phages from the City of Cape Town wastewater treatment plant in Athlone 
was unexpected as these treatment plants receive households and industrial waste usually in 
the form of sewage and are designed to remove contaminants and monitor faecal microbial 
pollutants (including E. coli counts) from these sources and treat the water to be recycled. E. 
coli counts tend to be very high in sewage 124,183, so it was expected that these samples would 
be filled with coliphages177–179. This has also been corroborated by a study that isolated two 
phages (OP7061 and OP10081) that were lytic against E. coli MG1655 from an urban sewage 
water plant called Opfikin in Switzerland183. Additionally, 42 virulent phages isolated from 
sewage water in Australia were all lytic against an E. coli K-12 strain derivative of which the 
MG1655 strain is a member124. Since none of the sources from this waste treatment plant 
contained phages, this may suggest that the coliform count is undetectable or that they are 
free of E. coli and therefore coliphages and that the byproducts from the treated water indeed 
have minimal contamination as desired by the City of Cape Town municipality. This was 
however, unanticipated since the coliform count in the effluent of the Athlone wastewater 
treatment plant has been shown to remain at relatively the same levels (1000 
counts/100ml), an arguably acceptable level for human contact184. 
 
The absence of phages in most faeces samples and sewage water was unexpected since 
literature suggests that coliphages are abundant in these samples however, since most of the 
phages in this study were isolated from sources with high water content (dam water, river 
mud, pond water), this supports the assumption made during this study that coliphages would 
be found in close proximity to their host, where we would also expect to find E. coli in 
abundance. 
 
4.1.2 Phage isolation from environmental samples using E. coli MG1655 strain 
 
 
Although it has previously been suggested that E. coli MG1655 is susceptible to a wide range 
of virulent phages15, this was not observed in this study as only 19% of the samples that were 
screened using this strain were confirmed to contain coliphages. Although this was not 
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confirmed in the MG1655 strain used in this study, there have been reports of newly acquired 
phage resistance mechanism by the MG1655 strain since its isolation from the E. coli K-12 
wildtype strain 122,185,186. E. coli and other gram-negative bacteria have been shown to modify 
or lose their phage receptors altogether to evade phage attack31. A mutant E. coli K-12 strain 
derivative that had its FhuA receptor removed through mutations in the N-globular domain 
(close to the -barrel channel of FhuA), became resistant to coliphage 80187. Another study 
with E. coli K-12 mutant strain derivatives, that had undetectable levels of phage receptor 
protein 3A due to a defect in the outer membrane composition, were found to be resistant 
to coliphage K3 185. FhuA is not only a phage receptor but also involved in the transport of 
ferrichrome and antibiotics (including rifamycin and albomycin187), whereas protein 3A is 
involved in conjugation and colicin sensitivity185. Other functions of these receptors are 
compromised as a result of receptor loss185,187, indicating that bacterial receptor loss can 
come with a fitness cost to the organism145. Regretfully, these mutations are then maintained 
in the population for generations, when natural selection is imposed by exposure to phages 
1,188. 
 
Spontaneous mutations are not the only mechanisms through which E. coli can develop 
resistance. Since most phage receptors are multifunctional, some bacterial hosts use 
structures such as extracellular polymers or proteins to block phage attachment 145. Since the 
polymers or proteins involved in this process are often involved in virulence, they have not 
yet been well documented in commensal strains of E. coli. However, some F+ strain derivatives 
of E. coli K-12 which uses the F factor for conjugation189, secrete TraT, a lipoprotein that 
modifies and disguises the outer membrane protein A (ompA) of E. coli which are receptors 
for multiple T phages185 hence blocking phage attachment. Additionally, phages also produce 
molecules that can block their own adsorption into bacterial hosts: T5, produces 
lipoprotein that binds to the outer membrane FhuA receptor found on E. coli K-12 strain 
derivatives including MG1655187. This lipoprotein is produced at the onset of phage 
infection and is thought to prevent superinfection185. As much as bacterial hosts have 
developed ways to protect themselves against phages, this has not stopped their phage 
opponents from evolving strategies that counteract these. Another approach that coliphages 
use to counteract bacterial phage-resistance mechanisms involve genetic recombination with 
another virulent phage, prophage or a non-phage entity (such as a bacteria). This then results 
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in the recognition of a different receptor on the same bacterial host185. Both these strategies 
result in an increase in phage infectivity thus expanding the phage host range 145. These 
altered phage protein(s) that evolve to interact directly with phage receptors on the surface 
of bacterial host are termed “anti-receptors”, and any changes to them are often confined to 
small sections of the protein that interact directly with the bacterial host190–192. 
 
 
Other less common mechanisms that bacterial hosts use to evade phage infection include the 
use of restriction enzyme modification and the CRISPR system, which is often observed 
following exposure to non-lytic phages193. Restriction modification systems function by 
cleaving foreign DNA (including phage DNA), resulting in non-viable phages 116. The E. coli 
MG1655 strain has been shown to contain restriction modification systems, such as EcoKI 
type I restriction modification system194. Provided that the invading phage does not get 
methylated by methylase enzymes encoded by the host bacterium, which would render the 
phage insensitive to the host restriction enzyme, restriction modification systems are often 
rapid thus protecting the bacterial host against invading phage genetic material193. Since 
CRISPR loci have previously been identified in E. coli MG1655 strain 195, it is possible that this 
system might have played a role in any possible phage resistance in this study. It has been 
debated for decades that the CRISPR system may not confer such an immune function in E. 
coli because their CRISPR sequences have not changed over time, as would be expected if 
they were incorporating foreign genetic material from phages196,197. However, a pivotal study 
by Cornelissen A. et al.198 suggested that CRISPR loci played a role in immunity to invading 
DNA in E. coli, using a laboratory strain of E. coli, called E. coli BL21AI that was protected 
against lysogenization and prophage induction by lambda phage when transformed with 
CRISPR encoding plasmids, despite not coding for any known CRISPR loci195. All of these phage 
resistance mechanisms may in part contribute to the rapid evolution of bacterial populations 
since they involve genetic variation as a means to ensure their survival, and any one of these 
mechanisms may have played a role in any possible evolution of the MG1655 strain used in 
this study that may have been accumulated since its derivation from its parental wildtype. 
Whole genome sequencing of the MG1655 strain used in this study would need to be 
performed to determine this conclusively. Although the removal of known prophages from 
the MG1655 E. coli strain in the 1990s should have made it highly permissive to phage attack, 
a previous study described four transducing coliphages that could not form plaques on the 
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MG1655 strain but could form plaques on the UPEC strains CFT073, UTI89, NU14,536 and 
J96162 suggests that in future it may be useful to screen the same environmental samples for 
phages using classic UPEC organisms which could have increased the chances of isolating 
more diverse phages. 
 
 
 
4.1.3 Phage isolation based on plaque morphology 
 
 
A total of 41 phages were isolated from separate plaques based on them having different 
sized and shaped morphologies. Turbid and irregularly-shaped plaques were excluded from 
the study for the following reasons: (a) turbid plaques often indicate that the phages are 
temperate and not virulent,123 and (b) plaques formed by virulent phages are generally round 
and clear in shape 94,123. Since the study aimed to isolate virulent phages that could be used 
for phage therapy, temperate phages were excluded because (a) they could result in the 
bacterial population acquiring phage resistance through selective pressure from the high 
titers of phages administered during phage therapy (hence hindering clearance of the 
bacterial infection being treated in the first place); (b) they could result in the introduction of 
unfavorable genetic segments such as pathogenicity islands, virulence factors; and (c) in some 
cases result in super-infection immunity. 70,71,152 
 
The majority of the plaques selected in this study were clear and transparent. However, three 
samples (17-10,17-5 and 17-3) all isolated from dam water from Dreyersdal farm, which 
contained tailed phages) had plaques with a “bull’s eye morphology” - with intense turbidity 
towards the periphery – which has previously been described for T-even phages (like T4)199. 
It has been suggested that this “bull’s eye” plaque morphology is a consequence of reduced 
lytic activity due to the bacterial lawn being over grown, or through inhibition of lysis by the 
bacterial host199,200. The inhibition of phage lysis allows for more time for the phages to 
mature which resulted in phages being adsorbed to already infected bacterial hosts, 
especially in cases where the host is present at low concentrations, thereby increasing the 
phage burst size (which reflects the average number of virions released per infected cell) and 
lengthening the period of phage dormancy117,199,200. Depolymerase activity is another 
phenomenon characterized by the appearance of a “bull’s eye” morphology for plaques198,201. 
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Double stranded DNA phages, like those belonging to the tailed families Myoviridae, 
Siphoviridae and Podoviridae, also encode depolymerases (including dextranases, 
xylosidases, peptidases and hyaluronidases) which degrade cell surface polymers (such as 
membrane lipids, peptidoglycan and lipopolysaccharides) such as K30 antigens in the cases of 
pathogenic strains that make up the extracellular matrix of the biofilm on the surface of E. 
coli strains, which may facilitate diffusion of phages through bacterial biofilms 198,201–203. Since 
E. coli MG1655 has also been shown to form type 1 fimbrae-mediated biofilms183, it is thus 
possible that the E. coli MG1655 strain used in this study for phage screening could have 
produced a biofilm that resulted in the formation of the bull’s eye plaque morphology 
observed for the three phage isolates. However, the formation of a biofilm by E. coli MG1655 
has only been demonstrated in liquid cultures183,204–206 and not in the type of double agar 
assay used in this study. It is possible that these strains behaved differently since the 
conditions of each assay system were distinct. 
 
Another property of plaque morphology that was observed was varying plaque sizes during 
the initial phase of phage isolation from environmental samples (using E. coli MG1655) and 
when the host range of each phage was subsequently tested (against ECOR UPEC strains). In 
general, plaques formed against the MG1655 strain were larger in size than those formed 
against UPEC strains. Plaque size has been shown to be affected by several factors 
including virus morphology, whereby phages with larger capsid diameters (such as those 
belonging to the Myoviridae family) result in plaques with smaller diameters than those with 
smaller capsid diameters (like phages belonging to the Siphoviridae family) 117,123. This is 
thought to be because larger viruses do not maneuver as easily through the top layer of agar 
as smaller viruses, which diffuse more freely and rapidly through sloppy agar to infect 
surrounding susceptible cells hence increasing the size of their plaques123. The length of the 
latent period is another factor thought to negatively affect plaque size. It is reasoned that the 
more viruses spend time within their bacterial host, the less they’ll be able to diffuse and 
travel to other surrounding hosts 123,207. Overall phages isolated in this study had varying 
plaque sizes in terms of size, turbidity and shape, phenotypes that are affected by the biology 
of the phage. To gain a better understanding of properties of plaque morphologies, 
understanding phage biology is paramount and critical parameters such latent period and 
adsorption rate of each phage isolate should be measured in future studies as they are also 
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implicated in phage therapy.                                                                                  
 
4.2 Phage host range testing against UPEC strains 
 
One of the advantages of using phages as therapeutics is their typically narrow host range, 
with most phages infecting only a few bacterial strains generally within the same bacterial 
genera116. To characterize the host range of phages isolated in this study, 11 UPEC strains 
from the ECOR panel were tested for susceptibility to each of the phage isolates. In total, 
31/41 of the isolated phages formed plaques against 7/11 of the UPEC strains. Phages 16-
3, 16-4, 16-5 and 16-7 displayed the highest lytic activity against these UPEC isolates, 
infecting 4/11 UPEC strains. Interestingly, all four phages were isolated from the same raw 
milk source, which was harvested from cattle farmed at Schaapkraal Farm, Ottery, Cape 
Town. Although this sample yielded phages with the highest lytic activity against UPEC 
strains, only two families were represented in these four phages: Myoviridae (3/4 phages) 
and Siphoviridae (1/4 phages). It is not unusual for Myoviridae phages to have a broad host 
range, as a previous study investigating the host range of three phages (ACG-C91, ACG-C40 
and ACG-M12) against biofilm-forming UPEC strains also found that the Myoviridae phages 
had the broadest host range119. Another study investigating the host range of T4 phages 
found that they lysed 41% of the UPEC isolates that were tested59. The high lytic activity of 
these four phages against UPEC strains possibly indicates how well adapted they are in 
infecting UPEC strains and that they might be identical especially since three of the (16-3, 
16-4 and 16-5) could all infect similar strains. A property that has been previously 
favored in choosing phage agents in studies similar to this one120,171,208. 
 
In contrast to these highly lytic phages, ten phages could not infect any of the 11 UPEC strains 
and three of the UPEC strains were not susceptible to any of the phages tested. Of interest 
was the tendency of phages that could infect UPEC strains to have similarities in their 
infectivity pattern. It was rationalized that phages from the same environmental source with 
the ability to form plaques against similar strains are identical or closely related hence were 
grouped together as one phage since they appeared to be clones of other samples. Although 
31 pure phages isolates were evaluated in this study, it is likely that there were only nine 
different phages (Table 3.2). 
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4.2.1 Characteristics of UPEC strains that could influence phage host range 
 
 
Another factor that could have affected the host range spectrum of the panel of phages tested 
in this study was the UPEC strains that were used. The strains used in this study were all 
clinical isolates from the ECOR collection. UPEC strains are primarily found in the gut, another 
primary reservoir of coliphages14,209,210, suggesting that some of them might have previously 
interacted with these phages in the gut. This interaction could have resulted in some of the 
UPEC strains acquiring prophages that would influence a number of phenotypic traits to the 
bacterial host. Although this study did not evaluate the presence of prophages in these UPEC 
isolates, their presence has been demonstrated previously in other UPEC isolates. Analysis of 
UPEC 26-1, a highly virulent strain of UPEC isolated from a patient with a UTI in Korea, was 
shown to contain as many as eight prophage sequences211. Similarly, genomic annotation of 
another UPEC strain - UTI89 - revealed the presence of the prophage P4 integrase a gene 
encoding the integrase protein only utilized by temperate phages when integrating their 
genomes into their bacterial hosts212. The major concern with acquiring prophages is that it 
has been linked to superinfection immunity in the bacterial hosts, which often inhibits 
infection by other phages70,71. 
 
Some phages, like those belonging to the Siphoviridae family, can undergo both a lytic and 
lysogenic lifecycle. It is therefore likely that provided these phages are undergoing the 
lysogenic lifecycle, they could have a smaller spectrum if some of these UPEC strains are 
harboring prophages. This could explain why three UPEC strains namely; ECOR-60, ECOR-62 
and ECOR-64 used in this study were not susceptible to any of the isolated phage as they 
could be harboring prophages preventing superinfection. Additionally, two of these strains 
(ECOR-60 and ECOR-64) are cystitis causing UPEC strains, 213 which have been shown to 
encode a plasmid pEC14_114 214 with high sequence similarity to plasmid pUTI89 which has 
been associated with intracellular invasion. Plasmid pUTI89 is encoded by UPEC UTI89 and is 
believed to have acquired this plasmid through horizontal gene transfer mediated by 
phages215. Phage transduction has been linked to superinfection immunity153,154 possibly 
explaining the lack of susceptibility of these two strains to phages tested in this study. 
However, this does not account for the resistance of ECOR-62 strain to phage lysis since it is 
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not a cystitis causing strain. It is clear that genome plasticity is quite common amongst 
pathogenic strains of E. coli and often associated with pathogenesis214–216. 
 
The two pairs of the CRISPR loci were also found in all of the 72 strains of the ECOR 
collection217,218, suggesting that this CRISPR mechanism could have played a role in phage 
resistance and the limited phage host ranges generally noted in this study. However, the 
majority of UPEC strains belonging to E. coli phylogenetic group B2 do not have the CRISPR 
system197. In the context of this study, it would suggest that strains not belonging to 
phylogenetic group B2 (including UPEC strain ECOR-11, -14, -40, -48, -50, -71 and -72) 
would have the CRISPR system that might contribute to phage resistance. However, this 
was not tested in the current study. Strikingly, strains ECOR-60, -62 and -64, belonging to 
phylogenetic group B2 were not susceptible to any of the phage isolates tested, even 
though strains belonging to this group were previously described as being devoid of the 
CRISPR system197. In addition to this UPEC strain produce the K1 capsule, a structure of 
polysaccharide often associated with septicemia and can block the adsorption of 
coliphage T7 by secreting this capsule186.This data suggests that there are other 
mechanisms by which UPEC strains resist infection by the phages that were isolated or that 
these UPEC strains are just biologically not susceptible to the phages because they lack 
the correct entry receptors. 
 
A number of other non-genetic factors could have affected the host range spectrum of 
phages. For instance, the propagating E. coli strain (MG1655 in this study) used to isolate 
phages could influence whether or not the isolated phages were able to infect other bacterial 
strains. A study that used the UPEC strain CFT073 used to isolate 49 unique phages, found 
that the same strain was resistant to an E. coli K-12 phage P1162. The implication of this being 
that had phage P1 been isolated using the K-12 strain and had the phage been used to infect 
strain CFT073, it might have not been susceptible to that phage. Therefore, it is possible that 
using the E. coli MG1655 strain to screen for phages that targeted UPEC strains was not ideal 
in this study. A UPEC strain should instead have been used to isolate phages from these 
environmental samples and even to enrich for the phages that were isolated. 
 
Other non-genetic factors that may have influenced phage host range include the 
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concentration of bacteria that was used, properties of the bacterial culture medium (such as 
pH or temperature) which may have affected the viability of the phages123. Since this study 
focused on isolating phages from convenient environmental samples in Cape Town that were 
not yet identified, their ideal conditions of growth were not yet determined. This is something 
that should be considered once the panel of novel phages have been sequenced and 
annotated to gain a better understanding of their genetic background and biological 
properties. In general, phages isolated in this study had a relatively narrow host range. This 
suggests that they have good potential for use in phage therapeutics. However, their ability 
to infect an E. coli strain, such as MG1655, that was originally isolated from the human gut 
and therefore represent a human commensal212 may pose a challenge. 
 
4.3 Characterization of phage morphology by TEM 
 
 
The majority of the phages screened in this study mapped to four known phage families, with 
the majority of the phages belonging to the order Caudavirales of tailed phages 92. Since order 
Caudavirales makes up approximately 96% of phages in nature93 it was not a surprise to have 
isolated many tailed phages. In addition, three samples appeared to contain phages that 
could not be identified since their morphologies did not match that of any of the previously 
characterized phages. 
 
The majority of the phages isolated in this study appeared to belong to the phage family 
Myoviridae, previously shown to harbor some of the most well characterized coliphages, 
including T-even phages92,93. There have been several previous studies59,119,121 that isolated 
coliphages belonging to this family from natural resources, suggesting their abundance in 
nature and their ability to survive under diverse environmental conditions, adapted to their 
target hosts119. Despite this study having isolated more phages belonging to the Myoviridae 
family than any of the other phage families, TEM analysis of tailed phages isolated in nature 
indicated that Siphoviridae phages are the most abundant of all tailed phages, making up 61% 
of the tailed phage group, while Myoviridae phages made up only 25% and Podoviridae only 
made up 14%92. In line with this, the second most abundant phages identified in this study 
belonged to the Siphoviridae family. Since Siphoviridae phages are temperate phages and can 
therefore undergo both the lytic and lysogenic lifecycles, it is possible that these phages were 
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underrepresented as they could have resulted in turbid plaque morphologies that were specifically 
excluded in this study.                                                                                                                        
 
The seven phages (16-1 to 16-7; all from raw milk) that could not reproduce plaques were 
visible by TEM. Of these seven, six were structurally similar and appeared to belong to the 
phage family Myoviridae known for their rigid, contractile tails with tail fibers which they use 
for adsorption92 and one belonged to the family Siphoviridae known for their long, thin and 
non-contractile tails which often acquire an S-spiral morphology. Four of these phages (16-
3, 16-4, 16-5 and 1-7) had the broadest host range against UPEC strains. The inability of 
these seven phages to reproducibly form plaques could be attributable to a known 
mechanism in phages whereby lysis is inhibited. Lysis inhibition has been most commonly 
described for T phages, belonging to the family Myoviridae.20,63 It often occurs when the 
number of infected bacterial hosts exceeds that of uninfected hosts, and this state is thought 
to exist to prolong the latent period of phages to allow for a larger phage burst size219. 
Although this process usually ends up with lysis of the bacterial host, it can delay the 
process by several hours219, which does not provide the phage with enough time to lyse 
the hosts. The loss of phage virulence could have also have resulted in the lack of ability to 
reproducibly form plaques 123. For instance, injecting DNA material into the host is a 
temperature dependent process for Lambda phage and that this phage cannot inject its DNA 
at temperatures below 220C, which results in in a non-successful infection of the bacterial 
host 220. Similarly, phage T4, a T-even Myoviridae phage that cannot be fully assembled to 
lyse its host at temperatures below 190C 
221. Considering the vast number of coliphages that exist in a variety of ecosystems and niches, 
the anticipation was for them to be able to survive in diverse environmental conditions thus 
their inability to reproduce plaques was unexpected. 
 
One of the requirements in using phages as therapeutics is that the phage lysate has to be 
thoroughly purified to avoid host protein contamination or phage mixtures. While apparently 
pure phage preparations were evident in the majority of the samples evaluated, some 
samples appeared to have mixed phages populations. As this study was focusing on lytic 
phages only, Inoviridae phages were intentionally disregarded since they are generally 
temperate92,97 and hence should have turbid plaques. Unfortunately, of these 12 “mixed” 
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phage samples, 10 were found to contain phages belonging to the Inoviridae family, with four 
of these being a mixed population with Siphoviridae phages and three being mixed with 
Myoviridae phages. This “mixed” Inoviridae sample may explain why these plaques appeared 
clear, as turbid Invoviridae phage plaques could have been masked by clear plaques formed 
by Siphoviridae phages and Myoviridae phages. However, three samples (16-11, 16-12b and 
16-15b) only contained Inoviridae phages, suggesting a problem with the isolation process. 
A major cause of mixed phage populations comes from phages that are acquired through 
contaminated surfaces, often observed in the dairy industry222,223. In addition to mixed phage 
populations, some samples appeared to have either individual phage heads and capsids 
observed by TEM, that may have resulted from mechanical shearing during the stringing 
process or from incomplete phage assembly121. 
 
Despite there are 13 families of phages that have been classified; only four families were 
identified in this study. This could have been affected by the strain of E. coli that was used to 
screen the environmental samples for the presence of phages. As previously mentioned, the 
strain of E. coli that is used to propagate phages can select for certain types of phage 
morphologies. Conversely, certain phage morphotypes may not be isolated hence resulting 
in underrepresentation of some phage families. This has been previously demonstrated 
whereby phages of several different morphotypes were isolated from the same human stool 
from an infant with diarrhea, depending on which different indicator bacterial strains were 
used: when E. coli strain C was used as a selecting host strain, phages belonging to the family 
Siphoviridae were isolated224; when E. coli K803 was used to select, phages with T4-like 
morphology belonging to the family Myoviridae were isolated128. 
 
 
4.4 Limitations and prospects 
 
 
The use of a commensal E. coli strain such as MG1655 to isolate pathogenic strains (UPEC) 
was one of this study’s main limitations, as this could have overestimated the number of 
potential phages that can be used for the treatment of bacterial pathogens that were less 
permissive to phages and could result in selection of phages that were infectious to human 
commensal E. coli strains. Since it is also known that bacterial strains used to propagate the 
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phages can affect the types of phages isolated, so using the “wrong” propagating strain may 
lead to underrepresentation of certain phages and limit potential phage agents that can be 
used as therapeutics. Future directions for this study will be to use a UPEC strain that has high 
sequence homology to strains against which the phages are to be isolated. Additionally, this 
UPEC strain must first be sequenced to ensure that it does not harbor any prophages that 
may be conducive to superinfection immunity, phage resistance or antibiotic resistance for 
situations were an antibiotic-phage cocktail is to be used. The use of a UPEC strain to isolate 
phages is thought to also increase the bacteriolytic spectrum of the phages being isolated 
119,121. In addition to this, performing phage adaptation experiments which aim to 
aggressively increase the virulence of the phage against the target strain can also increase the 
phage spectrum of bacteriolytic activity162,119. This study also isolated Siphoviridae phages, 
which are known to both virulent and temperate. To differentiate between virulent and 
temperate Siphoviridae phages, they could be sequenced in future to check for the presence 
of genes that may result in phage integration such integrase, cI and cII gene required for 
establishment and maintenance of lysogeny to confirm whether they are lytic or temperate99. 
Other critical parameters that may affect phage stability (such pH, temperature, detergents 
and organic solvents) should also be more carefully controlled for in future to ensure the 
stability and viability of phages. 
 
Adsorption rate, burst size and latency period are some of the major parameters of phage 
therapy that need to be measured. Although some of the phage advantages of phages as 
therapeutics exceed those of antibiotics, it should be noted that phages can be directly 
immunogenic to humans70,71. Prospective studies should focus on identifying immunogenic 
phage components to alleviate the risk of inducing host immune responses. Phage lysates 
should be thoroughly purified to ensure that crude phage lysates do not contain endotoxins 
such LPS that could react with the immune system once administered. Although phages are 
still more desirable than antibiotics, unlike antibiotics which can be broadly bactericidal or 
bacteriostatic142, phages tend to be highly bacterial host-specific and therefore the disease-
causing microbes would first have to be isolated and identified from individual patients and 
then screened for phage sensitivity in vitro before they could be administered as treatment85. 
Finally, although the study aimed to conduct DNA sequence analysis of the isolated phages, 
this could not be achieved due to limited time. 
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4.5 Concluding remarks 
 
 
Overall, the data obtained from this study supports the hypothesis that coliphages are 
abundant in nature and can be enriched using a commensal E. coli strain. However, not much 
could be concluded about their diversity since most of the phages that were isolated were 
structurally similar, representing only four phage families and one group of phages which 
could not be identified. An analysis of the phage genomes would have shed more light on the 
phage diversity and the presence of pathogenicity islands, antibiotic resistance cassettes, and 
virulence factors, all of which should be considered for phage therapy. The abundance and 
diversity of coliphages and the easy cultivation techniques for their host makes them ideal to 
work with as therapeutics since they are relatively easy to isolate from nature and can survive 
in a vast number of environmental conditions. In addition, there are historically good reasons 
that make coliphages ideal for phage therapy; Félix d’Hërelle and his colleagues226 first 
described the use of coliphages to treat diarrhea caused by E. coli with good success rates. 
Moreover, there have been several reports on the successful use of coliphages for veterinary 
application in the United Kingdom227,228. None of the phages that have been described in the 
literature are infectious to all known pathogenic strains of E. coli, warranting the continued 
search for a novel highly lytic phage with a narrow host range. To date, most studies have 
described the lytic activity of coliphages in vitro, with only a few studies having done in vivo 
validation in animal models, such as mice and chickens.227,229 This warrants more in vivo 
studies that are followed by well-designed clinical trials. The global spread of antibiotic 
resistance continues to have hard-hitting implications for future of bacterial control that will 
impact the quality of lives of most humans and cause massive financial loss to health care 
systems around the world. With the significant recent progress in our understanding of phage 
biology and our growing appreciation of the advantages of phages compared to antibiotics to 
control bacterial pathogens in light of growing antibiotic resistance, phage therapy clearly has 
merit to be explored as therapeutics in the Western world.  
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